Intermittent dual vagus nerve modulation treatment for improved glycemic control in type 2 diabetes

Intermittent dual vagal modulation therapy using electrical blockade and stimulation of specific vagal nerve branches addresses the limitations of existing treatments, providing effective glycemic control with reduced side effects and patient-specific optimization.

JP2024541222APending Publication Date: 2024-11-08RESHAPE LIFESCIENCES INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2024524393
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-20
Filing Date
2022-10-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current treatments for type 2 diabetes, such as stand-alone vagotomy and vagus nerve stimulation, have undesirable side effects and are not tailored to patient compliance, and existing neuromodulation techniques show mixed results in glycemic control.

Method used

A novel approach involving intermittent dual vagal modulation therapy, combining reversible electrical blockade of the hepatic vagal nerve branch with simultaneous electrical stimulation of the celiac vagal nerve branch, using a system with electrodes and a pulse generator, optimized by artificial intelligence and machine learning for personalized treatment.

Benefits of technology

This method effectively regulates blood glucose levels without significant adverse effects, offering improved glycemic control and reduced risk of resistance, as demonstrated in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541222000001_ABST
    Figure 2024541222000001_ABST
Patent Text Reader

Abstract

Therapeutic methods and systems for the treatment and maintenance of patients with type 1 or type 2 diabetes. The various treatments described herein provide novel therapies that utilize nerve stimulation in conjunction with electrical blockade of nerve branches to provide safe and effective treatment of type 1 and / or type 2 diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application was filed on October 24, 2022 as a PCT international patent application claiming priority to and benefit of U.S. Application No. 63 / 271,064, filed on October 22, 2021, and U.S. Application No. 63 / 380,313, filed on October 20, 2022, the disclosures of which are incorporated herein in their entireties.

[0002] Introduction Obesity is a major risk factor for the development of type 2 diabetes, which affects over 31 million people in the United States. Adherence to type 2 diabetes medications and frequent glucose spikes continue to be challenges in the treatment of type 2 diabetes. New treatment options that can be tailored to patient adherence and blunt glucose spikes are needed. More permanent treatments such as stand-alone vagotomy or vagus nerve stimulation have led to undesirable or mixed results. The safety and reversibility of such treatments are also important concerns. Bioelectrical neuromodulation of vagus nerve branches that innervate organs that regulate plasma glucose may be a method for treating type 2 diabetes. There is a need to improve the treatment of type 2 diabetes.

[0003] Intermittent dual vagus nerve modulation treatment for improved glycemic control in type 2 diabetes The present disclosure provides neuromodulation / neuroregulation systems and methods for treating type 2 diabetes. The invention described herein relates to a novel, tunable, and localized approach for the treatment of type 2 diabetes via electrical blockade of the hepatic vagus nerve branch with simultaneous electrical stimulation of the celiac vagus nerve branch. The vagus nerve controls multiple organ systems that regulate blood glucose, such as the liver via the hepatic branch, and the pancreas via the celiac branch. There is mixed evidence that hepatic vagotomy may result in improved glycemic control. Nevertheless, there are inherent problems with nerve ligation: hepatic vagotomy is irreversible, patients may adapt to vagotomy over time, and peripheral nerves may regrow with unknown effects on the newly reinnervated end organs. Hepatic vagotomy may also cause negative changes in feeding behavior, increased hypoglycemic episodes, affect liver regeneration, and cause increased metastasis during liver cancer. Litigation is not the only option for inhibiting hepatic vagus nerve stimulation. Introducing a reversible electrical blockade of the hepatic branch of the vagus nerve has shown efficacy similar to litigation without the undesirable side effects.

[0004] Previous studies on electrical neuromodulation of the vagus nerve for the treatment of type 2 diabetes have shown mixed results. Chronic studies using stimulation or electrical conduction blockade of the vagus nerve have demonstrated increased glycemic control, however, weight loss may be an inadequate factor for many diabetic patients. Further stimulation studies of the vagus nerve or its branches have failed to increase glycemic control, with only a few studies demonstrating enhanced glucose regulation. The present invention combines the introduction of reversible electrical blockade to the hepatic branch of the vagus nerve with simultaneous stimulation of the celiac branch of the vagus nerve associated with the pancreas. The present invention has shown significant results in animal models.

[0005] More recent optogenetic and chemogenetic vagus nerve manipulations provide neurospecificity and may be utilized for glycemic control, but it should be noted that viral vector introduction and gene regulation presents real-time clinical challenges in humans. Alternatively, electrical neurostimulation has long-standing and proven clinical safety and efficacy in many therapeutic areas, such as cervical stimulation for epilepsy, pain management, deep brain stimulation, urinary bladder control, and other therapies. However, electrical neurostimulation is necessary for the treatment and management of type 2 diabetes. In addition, the methods of the system described herein also allow for the optimization of therapy settings and algorithms using artificial intelligence and machine learning.

[0006] In some aspects, the present disclosure provides systems and methods for Type 2 Diabetes Vagus Nerve Stimulation (T2D-VNS). In certain embodiments, the T2D-VNS system comprises a continuous glucose monitor (CGM), a stimulation electrode / lead cranially attachable to the celiac branch of the posterior vagus nerve (PVN), and a pulse generator (PG) either implanted or external in a closed loop with a programmer to change settings for therapy customization.

[0007] In some aspects, the present disclosure also provides a minimally invasive electrode implantation method. In certain embodiments, the method includes implanting an electrode in a subject to be treated using a minimally invasive laparoscopic technique with enhanced visualization of the posterior vagus nerve and the celiac branch for optimal electrode placement. This can be accomplished by ensuring laparoscopic positioning of the celiac branch for correct electrode placement on the PVN.

[0008] In some aspects, the disclosure provides various operating parameters for T2D-VNS. In certain embodiments, implementations of the method using selected operating parameters are effective to increase plasma glucose by at least about 20 mg / dL from a controlled clamp glucose level of 50 mg / dL within about 30 minutes after treatment in a subject.

[0009] In some aspects, the present disclosure provides for safe stimulation of the vagus nerve and end organs: little or no adverse behavior or organ damage is observed as a result of stimulation or gross necropsy from the animal studies presented in the examples of the present disclosure.

[0010] In some aspects, a system for treating type 2 diabetes in a subject includes: (1) at least one electrode adapted to be positioned on the posterior vagus nerve (PVN) or a celiac vagal branch of the PVN of the subject and to deliver an electrical signal to the posterior vagus nerve (PVN) or a celiac vagal branch of the PVN of the subject; (2) a pulse generator operably connected to the at least one electrode, the pulse generator comprising a power module and a programmable therapy delivery module, the programmable therapy delivery module configured to deliver at least one therapy program, the at least one therapy program including at least one electrical signal therapy applied to the PVN via the at least one electrode; and (3) external components including a communications system and a programmable storage and communications module, the programmable storage and communications module configured to store the at least one therapy program and communicate the at least one therapy program to the pulse generator. and (4) a glucose sensor operatively connected to the pulse generator and the external component, the glucose sensor configured to continually monitor plasma glucose of the subject and to detect an increase or decrease in the plasma glucose from a predetermined threshold level, wherein the pulse generator is triggered to deliver the at least one electrical signal therapy when the subject's plasma glucose is equal to or less than a first predetermined threshold, and the pulse generator stops delivering the at least one electrical signal therapy when the subject's plasma glucose is equal to or greater than a second predetermined threshold, the at least one electrical signal therapy comprising an electrical signal pattern having a frequency of about 1 Hz to about 200 Hz, a pulse width of about 0.1 milliseconds (ms) to about 10 ms in steps of about 0.1 ms, and a pulse amplitude of about 0.1 mA to about 12 mA in steps of about 0.1 mA, and the electrical signal therapy is configured to initiate neural stimulation to the subject's PVN.

[0011] In some embodiments, a method of treating type 2 diabetes in a subject includes applying at least one electrical signal therapy to the subject's posterior vagus nerve (PVN) or the celiac vagus nerve branch of the subject's PVN using the system.

[0012] In another example, a system for treating type 2 diabetes in a subject includes: (1) a first electrode positioned on a first nerve or organ and adapted to deliver an electrical signal to the first nerve or organ; (2) optionally a second electrode positioned on a second nerve or organ and adapted to deliver an electrical signal to the second nerve or organ; and (3) a pulse generator operatively connected to the first and / or second electrodes, the pulse generator comprising a power module and a programmable therapy delivery module, the programmable therapy delivery module configured to deliver at least one therapy program including a first therapy program and optionally a second therapy program, the first therapy program being a first therapy program. the first and / or second electrical signals are each configured to initiate activity on the first and / or second nerves or organs, respectively, the activity being nerve stimulation or nerve block; and (4) an external component including a communications system and a programmable storage and communications module, the programmable storage and communications module configured to store at least one therapy program and communicate the at least one therapy program to the pulse generator.

[0013] In some embodiments, a method of treating type 2 diabetes in a subject includes: (1) applying a first electrical signal to a first nerve or organ of the subject using the system of claim 1, where the first electrical signal initiates nerve stimulation or a nerve block; and (2) optionally applying a second electrical signal to a second nerve or organ of the subject using the system of claim 1, where the second electrical signal initiates nerve stimulation or a nerve block.

[0014] In some embodiments, the first and / or second electrical signals are each independently configured to upregulate or downregulate activity on the first and / or second target nerves or organs, respectively. In some embodiments, the first and second electrical signals are applied simultaneously, synchronously, intermittently, during substantially the same time, during substantially different times, or in a coordinated manner. In some embodiments, the first and / or second electrical signal treatments are each applied sequentially to the first target nerve or organ and / or the second target nerve or organ, respectively. In certain embodiments, the first electrical signal is an upregulation or stimulation signal.

[0015] In some embodiments, the method further comprises a glucose sensor configured to continuously monitor plasma glucose of the subject, the glucose sensor operatively connected to the pulse generator and the external component. In some embodiments, the glucose sensor is configured to detect an increase or decrease in plasma glucose from a predetermined threshold level. In some embodiments, the pulse generator is triggered to deliver the first and / or second electrical therapies when the subject's plasma glucose is equal to or less than a first predetermined threshold, and the pulse generator stops delivering the first and / or second electrical therapies when the subject's plasma glucose is equal to or greater than a second predetermined threshold.

[0016] In some embodiments, the first nerve or organ and the second nerve or organ are each independently selected from the group consisting of the vagus nerve, the anterior vagus nerve, the posterior vagus nerve, the hiatus of the posterior nerve, the hepatic branch of the vagus nerve, the celiac branch of the vagus nerve, the splanchnic nerve, the renal nerve, the renal artery, the sympathetic nerve, the baroreceptor, the glossopharyngeal nerve, the duodenum, the jejunum, the ileum, the small intestine, the colon, the stomach, the esophagus, the liver, the spleen, the pancreas, and combinations thereof. In certain embodiments, the first nerve or organ is the celiac branch of the posterior vagus nerve.

[0017] In some embodiments, the first nerve or organ and the second nerve or organ are different. In some embodiments, the first electrical signal is applied to the vagus nerve or the hepatic branch of the abdominal vagus nerve, centered on the bifurcation of the hepatic nerve. In some embodiments, the first electrical signal is applied to the vagus nerve or the celiac branch of the abdominal vagus nerve, centered on the bifurcation of the celiac nerve, liver, pancreas, or both.

[0018] In some embodiments, the first and / or second electrical signal each have an on-time and an off-time, and the off-time is selected to allow at least partial recovery of activity of the first and / or second nerve or organ. In some embodiments, the on-time is configured to initiate upon detection of a plasma glucose level of 50 mg / dL, or about 60 mg / dL, or about 70 mg / dL, or about 80 mg / dL. In some embodiments, the first and / or second electrical signal treatment is configured to change the plasma glucose level by at least about 5 mg / dL in about 10 minutes. In some embodiments, the first and / or second electrical signal treatment is configured to change the plasma glucose level by at least about 10 mg / dL in about 20 minutes. In some embodiments, the first and / or second electrical signal treatment is configured to change the plasma glucose level by at least about 20 mg / dL in about 30 minutes.

[0019] In some embodiments, the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz, about 0.1 Hz to about 100 Hz, or about 1 Hz to about 20 Hz, while in other embodiments, the first electrical signal has a frequency of about 200 Hz to about 10 kHz.

[0020] In some embodiments, the second electrical signal has a frequency of about 0.01 Hz to about 200 Hz, about 0.1 Hz to about 100 Hz, or about 1 Hz to about 20 Hz, while in other embodiments, the second electrical signal has a frequency of about 200 Hz to about 10 kHz.

[0021] In some embodiments, the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz, and the second electrical signal has a frequency of about 200 Hz to about 10 kHz.

[0022] In some embodiments, the first electrical signal and / or the second electrical signal each independently include a signal pattern, each signal pattern including pulses having a pulse width between about 10 microseconds and about 10,000 microseconds.

[0023] In some embodiments, the pulses of the first and / or second electrical signals are monophasic pulses, or biphasic pulses, or combinations thereof. In some embodiments, the first and / or second electrical signals each independently have an on-time of about 30 seconds to about 30 minutes. In some embodiments, the first and / or second electrical signals each independently have a current amplitude in the range of about 0.01 mAmps to about 20 mAmps. In some embodiments, the first and / or second electrical signals each independently include an abrupt start of the pulse, or an increase in current / voltage amplitude, or an increase in frequency, or an increase in pulse width, or combinations thereof, at or near the start of application of the first and / or second electrical signals.

[0024] In some embodiments, the first and / or second electrical signal therapies are configured to be applied multiple times per day and / or intermittently over multiple days, and the first and / or second electrical signals each have a frequency selected to upregulate (or downregulate) activity on the first nerve or organ, and have an on-time and / or an off-time, the off-time selected to allow at least partial recovery of activity of the first or second nerve or organ.

[0025] In some embodiments, the first and / or second electrical signal therapies are configured to be applied intermittently multiple times per day and over multiple days, and the first and / or second electrical signals each have a frequency selected to upregulate activity on the first nerve or organ and have an on-time and an off-time, the off-time selected to allow at least partial recovery of activity of the first nerve or organ.

[0026] In some embodiments, the programmable storage and communication module is configured to store and communicate two or more therapy programs, each therapy program distinct from the others and configured to be selected for communication.

[0027] In some embodiments, the sensor further comprises a transmitter operably connected to the glucose sensor, the transmitter configured to communicate data generated by the glucose sensor to an external communication device.

[0028] In some embodiments, the communication system is selected from the group consisting of an antenna, blue tooth technology, radio frequency, WIFI, light, sound, and combinations thereof, and the communication system is configured to communicate at least one parameter of the therapy program to an external communication device.

[0029] In some embodiments, a method of making a system for treating type 2 diabetes in a subject includes: (1) connecting a first electrode to a pulse generator and placing the first electrode on a first nerve or organ; (2) optionally connecting a second electrode to the pulse generator and placing the second electrode on a second nerve or organ; (3) configuring a programmable therapy delivery module of the pulse generator to deliver at least one therapy program including a first electrical signal therapy and optionally a second electrical signal therapy, where the first electrical signal therapy is configured to be applied to the first nerve or organ via the first electrode and the second electrical signal therapy is configured to be applied to the second nerve or organ via the second electrode, where the first and / or second electrical signals initiate nerve stimulation or nerve block, respectively; and (4) configuring a programmable storage and communication module of an external component to store the at least one therapy program and to communicate the at least one therapy program to the pulse generator.

[0030] Definitions and Interpretations of Selected Terms The term "about" is not intended to broaden or limit the extent of equivalents that may otherwise be given a particular value. The term "about" in the context of the present disclosure means a value within 10% (±10%) of the value immediately following the term "about", including any numerical value within this range, a value equal to the upper limit (i.e., +10%) of this range, and a value equal to the lower limit (i.e., -10%) of this range. For example, the value "100" encompasses any numerical value between 90 and 110, inclusive (except for "100%" which always has an upper limit of 100%).

[0031] In some examples, one or more components may be referred to herein as being "configured to," "configurable to," "operable / operative to," "adaptable to," "capable of," "adapted to," etc. Those skilled in the art will recognize that such terms (e.g., "configured to") can generally encompass active components and / or inactive components and / or standby components, unless the context requires otherwise.

[0032] As used herein, a "cycle" means one repetition of a repeating pattern of electrical signals. A "stimulation cycle" refers specifically to a low frequency stimulation signal.

[0033] As used herein, "simultaneously" generally means that in the context of multiple electrical signals being applied, the multiple electrical signals are applied synchronously or at about the same time, at least during one period of time.

[0034] As used herein, "duty cycle" refers to the percentage of time charge delivered to a nerve in one cycle. In embodiments, the duty cycle can be modified by reducing the pulse width and / or by adding inactive phases between pulses, or both.

[0035] "Frequency" as used herein means the reciprocal of a period measured in Hertz.

[0036] As used herein, "high duty cycle" refers to an electrical signal pattern having a duty cycle of about 76% or greater.

[0037] As used herein, "low duty cycle" refers to a signal pattern having a duty cycle of about 75% or less.

[0038] As used herein, "high frequency" generally refers to a frequency of about 200 Hz or higher. As used herein, "high frequency signal" generally refers to HFAC or HFAV having a frequency of about 200 Hz or higher. High frequency signals are used, in particular, to downregulate or block neural activity.

[0039] As used herein, "low frequency" generally refers to frequencies below about 200 Hz.

[0040] As used herein, a "low frequency signal" or a "low frequency stimulation signal" generally refers to a stimulation signal having a frequency of 199 Hz or less. The stimulation signal is used, among other things, to upregulate or stimulate neural activity.

[0041] As used herein, "HFAC" refers to high frequency alternating current.

[0042] As used herein, "HFAV" refers to high frequency alternating voltage.

[0043] As used herein, "Hz" refers to Hertz.

[0044] As used herein, "intermittent" refers to a treatment period not exceeding 60 minutes, more preferably not exceeding 45 minutes, and even more preferably not exceeding 30 minutes.

[0045] As used herein, "off-time" refers to a period of time during which no charge is delivered to a nerve. In embodiments, the off-time is on the order of seconds and / or minutes.

[0046] "On-time" refers to the period during which multiple microsecond and / or millisecond cycles and / or stimulation cycles and / or stimulation activity phases are applied to a nerve. In embodiments, on-time is on the order of seconds and / or minutes.

[0047] "Period" refers to the length of time of one charging phase and one recharging phase, and may include one or more pulse delays. "Stimulation period" refers specifically to the length of time of one charging phase and one recharging phase in a low frequency stimulation signal. The stimulation period may also include one or more pulse delays.

[0048] "Pulse amplitude" is the amperage or voltage height of a pulse relative to a baseline.

[0049] As used herein, "pulse delay" refers to a period of time during which the impedance across the parallel electrical pathway to the nerve is at or near 0 ohms, with the intent of avoiding any unwanted electrical signals being delivered to the nerve.

[0050] As used herein, "pulse width" refers to the length of time of a pulse.

[0051] As used herein, "ramp down" refers to a period at the end of the application of an electrical signal or between different patterns of electrical signals to a patient's nerve during which the pulse amplitude of the signal is reduced.

[0052] As used herein, "ramp up" refers to increasing the pulse amplitude at the beginning of an applied electrical signal or between different patterns of electrical signals until the desired amplitude for therapy is reached. The starting amplitude of ramping may be below the current / voltage threshold of the block.

[0053] As used herein, a "therapy cycle" refers to a discrete period of time that includes one or more on-times and off-times. The pattern of on-times and off-times within a therapy cycle can be repetitive, non-fixed, or random throughout the therapy schedule.

[0054] As used herein, "therapy parameters" include, but are not limited to, frequency, pulse width, pulse amplitude, on-time, off-time, and pattern of the electrical signal.

[0055] As used herein, "therapy schedule" refers to the time at which therapy cycles are initiated, the number of therapy cycles, the timing of the therapy cycles, and the delivery duration of the therapy cycles for at least one day per week.

[0056] As used herein, "nerve" generally includes a nerve or any portion thereof, including but not limited to nerve branches, nerve fibers, trunks, and branching points.

[0057] The "anterior vagus nerve (AVN)" or "anterior vagus trunk" innervates the anterior surface of the esophagus and is composed primarily of fibers from the left vagus nerve. The "posterior vagus nerve (PVN)" or "posterior vagus trunk" innervates the posterior surface of the esophagus and is composed primarily of fibers from the right vagus nerve. The anterior and posterior vagus nerves are two separate and distinct nerves.

[0058] As used herein, "hepatic branch" refers to the nerve branch of the anterior vagus nerve below the diaphragm. The hepatic branch includes any area from the anterior vagus nerve cranial to the hepatic branch. In particular, the hepatic branch carries afferent information from the pancreas to the brain and efferent information from the brain to the pancreas.

[0059] As used herein, "celiac branch" generally refers to the nerve branch of the posterior vagus nerve below the diaphragm. The celiac branch includes any area from the posterior vagus nerve cranial to the celiac branch. In particular, the celiac branch carries afferent information from the pancreas to the brain and efferent information from the brain to the pancreas.

[0060] "Celiac fibers" as used herein refers to afferent or efferent axons that travel within the length of the vagus nerve between the pancreas and the brain. Afferent axons travel from the pancreas through the celiac branch of the vagus nerve, where they travel to the posterior vagus nerve below the level of the diaphragm. Afferent axons then enter the thoracic cavity, primarily in the right cervical region. Afferent axons then enter the brainstem and form synaptic connections. Efferent fibers are part of the parasympathetic nervous system. The preganglionic cell bodies of the efferent fibers are in the brainstem and travel the length of the vagus nerve (as do afferent fibers) in close proximity to the pancreas to its postganglionic neurons.

[0061] "Liver fibers" as used herein refers to afferent or efferent axons that travel within the length of the vagus nerve between the liver and the brain. Afferent axons travel from the liver through the hepatic branch of the vagus nerve, where they travel to the anterior vagus nerve below the level of the diaphragm. Afferent axons then enter the thoracic cavity, primarily in the left cervical region. Afferent axons then enter the brainstem and form synaptic connections. Efferent fibers are part of the parasympathetic nervous system. The preganglionic cell bodies of efferent fibers are in the brainstem and travel the length of the vagus nerve (similar to afferent fibers) close to the liver to its postganglionic neurons.

[0062] Where a range is provided, the range includes both endpoints and all real numbers therebetween, for example the range 200 Hz to 25 kHz includes, for example, 201 to 25 kHz, 202 to 25 kHz, as well as 24,999 Hz to 200 Hz, 24,998 Hz to 200 Hz, and 201 Hz to 24,999 Hz, 202 Hz to 24,998 Hz.

[0063] The subject matter of embodiments of the present disclosure will now be described with reference to the various drawing figures, in which like elements are numbered like throughout.

[0064] The following images illustrate certain aspects of the present invention and are incorporated in and constitute a part of this specification. A brief description of the figures follows: [Brief description of the drawings]

[0065] [Figure 1] Illustrates the vagus nerve, associated pathways, and associated organs. [Diagram 2] The locations of the blocking and stimulating electrodes are illustrated. [Diagram 3] FIG. 1 shows a schematic diagram of an exemplary system including a pulse generator and a lead that includes electrodes placed on the anterior vagus nerve (AVN) and posterior vagus nerve (PVN). [Figure 4] 1 shows a schematic representation of another exemplary system, according to various embodiments of the present disclosure. [Diagram 5]1 illustrates an exemplary architecture of a computing device that can be used to implement aspects of the present disclosure. [Figure 6] 4 is a flow chart illustrating an exemplary method of operating the system. [Figure 7] 1 illustrates another exemplary HVNS system in a disassembled configuration with its individual components according to Example 1. [Figure 8] 1 shows a schematic diagram of a system in which an implantable glucose sensor communicates with a pulse generator to initiate vagus nerve stimulation. [Figure 9] A schematic diagram of a system is shown in which an implantable glucose sensor first communicates with an external device attached to the outside of the skin, and then communicates with a pulse generator to initiate vagus nerve stimulation. [Figure 10] Block and stimulus signals at 5000 Hz and 1 Hz square waves, respectively, are shown. [Figure 11] 1 shows the change in plasma glucose in rats as a result of the disclosed treatment compared to a sham treatment during and after intravenous glucose administration in rats. [Figure 12] 1 shows the change in plasma glucose in rats as a result of the disclosed treatments compared to experimental treatments. [Figure 13] A representative compound action potential evoked by electrical stimulation below the level of the diaphragm is shown. [Figure 14] 1 shows the intensity-duration curves showing the stimulation threshold of the vagus nerve CAP. The curves are fitted to a power function. [Figure 15] Current-effect curves of CAP amplitudes recorded immediately after the 5000 Hz off-ramp at locations proximal and distal to the nerve are compared. [Figure 16] FIG. 1 shows recovery of CAP amplitude after complete block at 8 mA. [Figure 17] FIG. 1 shows blood glucose levels after injection of intravenous glucose before and after application of alloxan. [Figure 18]FIG. 1 shows the insulin response 3 min after intravenous glucose injection before and after application of alloxan. [Figure 19] 1 shows the change in plasma glucose in pigs before and after electrode implantation. [Figure 20] 1 shows the change in plasma glucose in pigs as a result of the disclosed treatments compared to sham controls. [Figure 21] 1 shows high frequency alternating current in alloxan-treated pigs. [Figure 22] 1 shows the variation in plasma glucose in pigs receiving the disclosed treatments compared to pigs receiving a sham treatment. [Diagram 23] 1 shows plasma glucose in pigs receiving the disclosed treatments over time compared to pigs receiving intermittent or sham treatments. [Figure 24] 4 shows the histopathology of various tissues after application of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0066] Therapy System In some aspects, the present disclosure provides systems and devices for treating conditions associated with type 2 diabetes. The systems generally include a pulse generator that provides a signal to modulate neural activity on a target nerve or organ.

[0067] In some embodiments, a system according to the present disclosure comprises an implantable pulse generator comprising at least one electrode operably connected to the implantable pulse generator, the electrode adapted to be placed on a target nerve and / or target organ of a subject, a power module, a programmable therapy delivery module configured to deliver at least one therapy program to the target nerve including an electrical signal therapy applied intermittently multiple times throughout the day and over multiple days, the electrical signals having a frequency selected to upregulate (for nerve stimulation) and / or downregulate (for nerve block) neural activity on the target nerve and / or organ and having on-times and off-times, the off-times selected to allow at least partial recovery of activity of the target nerve or organ, and an external component including an antenna and a programmable storage and communications module, the programmable storage and communications module configured to store the at least one therapy program and communicate the at least one therapy program to the implantable pulse generator.

[0068] In some embodiments, the system may include two electrodes, e.g., a first electrode and a second electrode, each operably connected to an implantable pulse generator. The first electrode is positioned on a first nerve or organ of the subject and adapted to deliver an electrical signal to the first nerve or organ. The second electrode is positioned on a second nerve or organ of the subject and adapted to deliver an electrical signal to the nerve or organ of the subject. The system may include at least two therapy programs, e.g., a first therapy program and optionally a second therapy program. The first therapy program includes a first electrical signal treatment applied to the first nerve or organ via the first electrode, and the second therapy program includes a second electrical signal treatment applied to the second nerve or organ via the second electrode. The first and / or second electrical signals are each configured to initiate an activity on the first and / or second nerve or organ, respectively, the activity being nerve stimulation or nerve block.

[0069] Referring now to Figure 3, one exemplary system according to the present disclosure and various aspects thereof is described. In the illustrated example, the system for treating type 2 diabetes or a condition associated with type 2 diabetes includes a pulse generator 104, an external portable charger 101, and two electrical lead assemblies 106, 106a. The pulse generator 104 is adapted to be implanted within the subject to be treated. In some embodiments, the pulse generator 104 is implanted just below the subject's skin layer 103. In related embodiments, the system includes one or more pulse generators 104.

[0070] In some embodiments, the lead assemblies 106, 106a are electrically connected to the circuitry of the pulse generator 104 by conductors 114, 114a. Industry standard connectors 122, 122a are provided for connecting the lead assemblies 106, 106a to the conductors 114, 114a. As a result, the leads 116, 116a and the pulse generator 104 may be implanted separately, and after implantation, the leads 116, 116a may be left in place while the originally placed pulse generator 104 is replaced by a different pulse generator.

[0071] The lead assembly 106, 106a upregulates and / or downregulates the nerves of the target based on the therapy signal provided by the neuroregulator 104. In one embodiment, the lead assembly 106, 106a includes distal electrodes 212, 212a that are positioned on one or more target nerves or target organs of the target. For example, the electrodes 212, 212a may each be individually positioned on the celiac nerve, vagus nerve, celiac branch of the vagus nerve, hepatic branch of the vagus nerve, or any combination thereof, of the target to be treated. For example, the lead 106, 106a has distal electrodes 212, 212a that are individually positioned on the PVN and AVN of the target, for example, directly below the patient's diaphragm. Fewer or more electrodes may be positioned on or near fewer or more nerves. In some embodiments, only one electrode is positioned on the PVN of the target, and no more electrodes are positioned on any other nerves or organs of the same target. In some embodiments, the electrode is a cuff electrode.

[0072] The external portable charger 101 includes circuitry for communicating with the implanted neuroregulator (pulse generator) 104. In some embodiments, the communication is a bidirectional radio frequency (RF) signal path across the skin 103, as indicated by arrow A. Exemplary communication signals transmitted between the external charger 101 and the neuroregulator 104 include treatment instructions, patient data, and other signals, as described herein. Energy or power may also be transferred from the external charger 101 to the neuroregulator 104, as described herein.

[0073] In the illustrated example, the external charger 101 can communicate with the implanted neuroregulator 104 by bidirectional telemetry (e.g., via radio frequency (RF) signals). The external charger 101 shown in FIG. 1 includes a coil 102 capable of sending and receiving RF signals. A similar coil 105 can be implanted within the patient and coupled to the neuroregulator 104. In one embodiment, the coil 105 is integral to the neuroregulator 104. The coil 105 functions to receive signals from and transmit signals to the coil 102 of the external charger 101.

[0074] For example, the external charger 101 can encode information as a bit stream by amplitude or frequency modulating an RF carrier. The signal transmitted between the coils 102, 105 preferably has a carrier frequency of about 6.78 MHz. For example, during the information communication phase, the value of a parameter can be transmitted by switching the rectification level between half-wave rectification and no rectification. However, in other embodiments, higher or lower carrier frequencies can be used.

[0075] In one embodiment, the neuroregulator 104 communicates with the external charger 101 using a load shift (e.g., a modification of the load induced on the external charger 101). This change in load can be sensed by the inductively coupled external charger 101. However, in other embodiments, the neuroregulator 104 and the external charger 101 can communicate using other types of signals.

[0076] In one embodiment, the neuroregulator 104 receives power for generating the therapy signal from an implanted power source 151, such as a battery. In a preferred embodiment, the power source 151 is a rechargeable battery. In some embodiments, the power source 151 can provide power to the implanted neuroregulator 104 when the external charger 101 is not connected. In other embodiments, the external charger 101 may also be configured to provide periodic recharging of the internal power source 151 of the neuroregulator 104. However, in alternative embodiments, the neuroregulator 104 can be entirely dependent on power received from an external source. For example, the external charger 101 can transmit power to the neuroregulator 104 via an RF link (e.g., between the coils 102, 105). In further embodiments, charging of the rechargeable battery 151 in the neuroregulator 104 can be accomplished by application of remote wireless energy. (Grajski et al, IEEE Microwave Workshop series on Innovative Wireless Power Transmission: Technology, Systems, and Applications, 2012 published on a4wp.org)

[0077] In some embodiments, the neuroregulator 104 initiates the generation and delivery of therapy signals to the lead assemblies 106, 106a. In one embodiment, the neuroregulator 104 initiates therapy when powered by the internal battery 151. However, in other embodiments, the external charger 101 triggers the neuroregulator 104 to begin generating therapy signals. After receiving a start signal from the external charger 101, the neuroregulator 104 generates therapy signals (e.g., pacing signals) and transmits the therapy signals to the lead assemblies 106, 106a.

[0078] In other embodiments, the external charger 101 can also provide instructions (e.g., pulse width, amplitude, frequency, wave phase, and other such parameters) for which the therapy signal is generated. In some embodiments, the external component comprises a communication system and a programmable storage and communication module. Instructions for one or more therapy programs may be stored in the programmable storage and communication module. In a preferred embodiment, the external charger 101 includes a memory capable of storing several predefined programs / therapy schedules for transmission to the neuroregulator 104. The external charger 101 can also allow a user to select a therapy program / therapy schedule stored in the memory for transmission to the neuroregulator 104. In another embodiment, the external charger 101 can provide therapy instructions along with each initiation signal.

[0079] Typically, each of the therapy programs / schedules stored in the external charger 101 can be adjusted by an operator (such as a physician) to suit the individual needs of a subject (e.g., a patient being treated). For example, a computing device (e.g., a notebook computer, a personal computer, etc.) 100 may be communicatively connected to the external charger 101. Once such a connection is established, the operator can use the computing device 107 to program a therapy into the external charger 101 for either storage or transmission to the neuroregulator 104.

[0080] The neuroregulator 104 may also include a memory capable of storing therapy instructions and / or patient data. In some embodiments, the neuroregulator comprises a power module and a programmable therapy delivery module. For example, the neuroregulator 104 may store one or more therapy programs in the programmable therapy delivery module that indicate which therapies should be delivered to the subject. The neuroregulator 104 may also store therapy / treatment / patient data that indicates how the patient utilized the therapy system and / or responded to the delivered therapies.

[0081] In some embodiments, the external component and / or the neuromodulator are programmed with one or more therapy programs. One therapy program may include an electrical signal treatment applied intermittently multiple times per day and over multiple days, the electrical signal having a frequency selected to downregulate and / or upregulate activity on a first target nerve, and having an on-time and an off-time, the off-time selected to allow at least partial recovery of activity of the first target nerve. Another therapy program may include an electrical signal treatment applied continuously over multiple days, the electrical signal having a frequency selected to downregulate and / or upregulate activity on a first target nerve or organ. A second therapy program may include an electrical signal treatment applied intermittently multiple times per day and over multiple days, the electrical signal having a frequency selected to upregulate or downregulate activity on a second target nerve or organ, and having an on-time and an off-time, the off-time selected to allow at least partial recovery of activity of the second target nerve. The first and / or second therapy programs may be applied at the same time, at different times, or at overlapping times. The first and / or second therapy programs may be delivered at specific times and / or in response to a signal from a sensor. In some embodiments, the sensor is designed to measure the patient's plasma glucose level. In some embodiments, the off-time is configured to begin upon detection of a plasma glucose level between 50 mg / dL and 90 mg / dL. In some embodiments, the on-time is configured to begin upon detection of a plasma glucose level below 90 mg / dL, below 80 mg / dL, below 70 mg / dL, below 60 mg / dL, or below 50 mg / dL.

[0082] In some embodiments, the system further comprises a biosensor (not shown). The biosensor may be a separate unit integrated into the therapy system or may otherwise be operably coupled to the system. In embodiments, the biosensor is electrically connected to the system. In embodiments, the biosensor communicates wirelessly with the therapy system. In embodiments, the biosensor is operably coupled to a neuroregulator of the therapy system. For example, a sensing electrode SE of the biosensor may be added to monitor neural activity as a way of determining how to modulate neural activity and / or duty cycle. The sensing electrode may be an additional electrode to the blocking electrode, although it will be understood that a single electrode may perform both functions. The sensing electrode and the blocking electrode may be connected to a controller as shown in FIG. 1. Such a controller is the same as the controller 102 described above with the added functionality of receiving signals from the sensing electrode.

[0083] In some embodiments, the sensor may be a sensing electrode, a glucose sensor, or a sensor that senses other biomolecules or hormones of interest. When the sensing electrode SE produces a signal representative of the targeted maximum vagal activity or tone, the controller with the additional function of receiving the signal from the sensing electrode functions to modify and / or maintain the signal delivered to the electrode placed on the nerve branch / fiber. As described with reference to the controller 102, the controller with the additional function of receiving the signal from the sensing electrode can be remotely programmed with parameters of block / stimulation duration and no block / stimulation duration, as well as targets for initiating, maintaining, or stopping, or terminating, or otherwise manipulating the block signal and / or up-control signal.

[0084] When implementing the therapy system, depending on the subject's glucose value indicated by the glucose sensor, the system can apply responsive changes to the first and / or second electrical signals to control / maintain plasma glucose at a desired level.

[0085] In one particular embodiment, the system 100 includes a glucose sensor configured to continuously monitor the subject's plasma glucose, the glucose sensor operatively connected to the implantable pulse generator 104 and the external components. The glucose sensor is configured to detect an increase or decrease in plasma glucose from a predetermined threshold level. The implantable pulse generator 104 is triggered to deliver the first and / or second electrical therapy when the subject's plasma glucose is below a first predetermined threshold, and the implantable pulse generator stops delivering the first and / or second electrical therapy when the subject's plasma glucose is above a second predetermined threshold. The predetermined thresholds of plasma glucose are approximately 50 mg / dL and 90 mg / dL. In some embodiments, the on-time is configured to begin upon detection of a plasma glucose level below 90 mg / dL, below 80 mg / dL, below 70 mg / dL, below 60 mg / dL, or below 50 mg / dL.

[0086] The circuitry 170 of the external portable charger 101 may be connected to an external coil 102. The coil 102 is in communication with a similar coil 105 implanted within the subject and connected to the circuitry 150 of the pulse generator 104. Communication between the external portable charger 101 and the pulse generator 104 includes the transmission of pacing parameters and other signals, as will be described.

[0087] When programmed by signals from the external portable charger 101, the pulse generator 104 generates up and / or down control signals on the leads 106, 106a. As will be explained, the external portable charger 101 may have additional functionality in that it may provide periodic recharging of the battery in the pulse generator 104 and may also allow for record keeping and monitoring.

[0088] Although an implantable (rechargeable) power source for the pulse generator 104 is preferred, alternative designs may utilize an external power source, with power being transmitted to the implanted module via an RF link (i.e., between the coils 102, 105). In this alternative configuration, while externally powered, the source of the particular electrical signal may originate from either the external power unit or the implanted module.

[0089] The electronic energization package may be primarily external to the body, if desired. An RF power device may provide the required energy level. The implanted components may be limited to a lead / electrode assembly, coil, and DC rectifier. In such an arrangement, programmed pulses with desired parameters are delivered through the skin using an RF carrier, and the signal is then rectified to regenerate a pulse signal for application as a stimulus to the vagus nerve, modulating vagus nerve activity. This virtually eliminates the need for battery replacement.

[0090] However, an external transmitter must be carried by the subject (e.g., the patient himself), which is inconvenient. Also, detection is more difficult with a simple rectifying system, and activation requires more power than if the system were fully implanted. In any case, because the power requirements for most therapeutic applications are relatively small, fully implanted systems are expected to exhibit a relatively long service life, potentially reaching several years. It is also possible, although not highly desirable, to employ an external pulse generator with leads that extend percutaneously to the implanted neural electrode set, as previously described herein. The main problem encountered with the latter technique is the possibility of infection. The advantage is that the patient can undergo a relatively simple procedure to allow for a short-term examination to determine whether the condition associated with this particular patient's excess weight is suitable for successful treatment. If so, a more permanent implantation can be provided.

[0091] In some embodiments, the system is configured to apply an electrical signal to an internal anatomical feature of a subject. The system includes at least one electrode for implantation within the subject and placement on the anatomical feature (e.g., a nerve), and application of a signal to the electrode applies a signal to the feature. The implantable component is placed within the subject's body below the skin layer and has an implanted circuit connected to the electrode. The implanted circuit includes an implanted communication system. The external component has an external circuit with an external communication system for placement on the skin and is adapted to be electrically coupled to the embedded communication system across the skin via radio frequency transmission. The external circuit has a plurality of user interfaces including an information interface for providing information to a user and an input interface for receiving input from a user.

[0092] In some embodiments, the system is configured to apply electrical signals to different vagus nerve branches. For example, the esophagus passes through the diaphragm at an opening or hiatus. In the region where the esophagus passes through the diaphragm, a vagus nerve trunk (e.g., AVN or PVN) is disposed on the opposite side of the esophagus. It will be understood that the exact location of the AVN and PVN relative to each other and relative to the esophagus is subject to a wide range of variation within a patient population. However, for many subjects, the AVN and PVN are close to the esophagus at the hiatus where the esophagus passes through the diaphragm. The AVN and PVN may be divided into multiple trunks that innervate organs such as the pancreas, gallbladder, liver, stomach, and intestines. Generally, the AVN and PVN are still close to the esophagus and stomach (and have not yet branched extensively) in the region of the esophageal and stomach junction.

[0093] Now, referring to FIG. 4, another example of the present system useful for treating conditions associated with type 2 diabetes is illustrated and described. Referring to FIG. 4, the device comprises an implantable component comprising an electronic assembly 210 ("hybrid circuit") and a receiving coil 216, and a standard connector 217 (e.g., an IS-1 connector) for attachment to an electrode lead. Two leads are connected to the IS-1 connector for connection to the implanted circuit. Both have a tip electrode for placement on the nerve. A set screw is shown at 214, allowing adjustment of electrode placement. In some embodiments, a marker 213 is provided to indicate a dorsal or ventral lead. A suture tab 211 is provided to achieve implantation at a preferred site. In some embodiments, a strain relief 215 is provided. The subject to be treated receives an external controller including a communication system connected to a control circuit. The external control unit can be programmed for various signal parameters including options such as frequency selection, pulse width, pulse amplitude, duty cycle, etc.

[0094] In some embodiments, the nerves AVN and / or PVN are indirectly stimulated by passing an electrical signal through the tissue surrounding the nerve. In some embodiments, the electrodes are bipolar pairs (i.e., alternating anodal and cathodal electrodes). In some embodiments, multiple electrodes may be placed on the AVN and / or PVN. As a result, energizing the multiple electrodes applies a signal to the AVN and / or PVN and / or their branches. In some therapeutic applications, some of the electrodes may be connected to an up-regulating electrical signal source (e.g., having a low frequency and other suitable parameters, as described below), and other electrodes may apply a down-regulating signal (e.g., having a high frequency and / or other suitable parameters, as described below). In some embodiments, only a single electrode array may be used with all electrodes connected to the up-regulating or down-regulating signal. In some therapeutic applications, some of the electrodes may be connected to an up-regulating electrical signal source (e.g., having a suitable frequency and other parameters, as described below).

[0095] In other embodiments, multiple electrodes are placed on the hepatic and / or celiac branches of the AVN and / or PVN nerves. In some therapeutic applications, some of the electrodes may be connected to an up-control electrical signal source (having low frequency and other suitable parameters, as described below), and other electrodes may apply a down-control signal. In some therapeutic applications, the electrode connected to the block electrical signal is placed on the hepatic branch of the vagus nerve. In other therapeutic applications, the electrode connected to the up-control signal is placed on the celiac branch of the vagus nerve. In still other therapeutic applications, a first electrode connected to the up-control signal is placed on the hepatic branch and a second electrode connected to the down-control signal is placed on the celiac branch.

[0096] The electrical connection of the electrodes to the pulse generator can be as described above, by having leads (e.g., 106, 106a) that connect the electrodes directly to the implantable pulse generator (e.g., 104), or, as described above, the electrodes can be connected to an implanted communication system for receiving signals to energize the electrodes.

[0097] The two electrode pairs may be connected to a pulse generator for a bipolar signal. In another embodiment, a portion of the vagus nerve is dissected away from the esophagus. An electrode is placed between the nerve and the esophagus. Another electrode is placed over the vagus nerve on the opposite side of the nerve to the first electrode, with the electrodes aligned axially (i.e., directly across each other). Although not shown for ease of illustration, the electrodes may be carried on a common carrier (e.g., a PTFE or silicone cuff) that surrounds the nerve VN. Other possible arrangements of electrodes are described in US2005 / 0131485, the disclosure of which is incorporated herein by reference in its entirety.

[0098] Any of the aforementioned electrodes can be flat metal pads (e.g., platinum), but the electrodes can be configured for a variety of purposes. In one embodiment, the electrodes are carried on a patch. In other embodiments, the electrodes are split into two portions, both connected to a common lead and both connected to a common patch. In some embodiments, each electrode is connected to a lead and positioned to deliver therapy from one electrode to the other. Flexible patches allow for articulation of portions of the electrodes to relieve stress on the nerve.

[0099] The system may include software that enables use of the system 100 in various programmable therapy schedules, electrical signal delivery, therapy programs, operating modes, system monitoring, and interfaces, as described herein. In embodiments, the system software may be stored on various computing devices, such as an external smartphone or tablet, an external programmer, a neuroregulator, and / or an external charger.

[0100] Referring now to Figure 5, an exemplary architecture of a computing device that can be used to implement aspects of the present disclosure is shown. For example, the external charger 101, the neuroregulator 104, the external programmer, the external smartphone of the tablet, or the various systems and devices of the therapy system 100 may be implemented with at least some of the components of a computing device as shown in Figure 5. Such a computing device is shown herein as reference number 300. The computing device 300 is used to execute the operating system, application programs, and software modules (including the software engine) described herein.

[0101] Computing device 300 includes at least one processing device 302, such as a central processing unit (CPU), in some embodiments. Various processing devices are available from various manufacturers, such as Intel or Advanced Micro Devices. In this example, computing device 300 also includes a system memory 304 and a system bus 306 that couples various system components, including the system memory 304, to the processing device 302. The system bus 306 can be one of several types of bus structures, including a memory bus or memory controller, a peripheral bus, and a local bus using any of a variety of bus architectures. Examples of computing devices suitable for computing device 300 include desktop computers, laptop computers, tablet computers, mobile devices (such as a smartphone, an iPod® mobile digital device, or other mobile device), or other devices configured to process digital instructions.

[0102] The system memory 304 includes a read-only memory 308 and a random access memory 310. A basic input / output system 312, containing the basic routines that act to transfer information within the computing device 300, such as during start-up, is typically stored in the read-only memory 308.

[0103] Computing device 300 also includes a secondary storage device 314, in some embodiments such as a hard disk drive for storing digital data. The secondary storage device 314 is connected to the system bus 306 by a secondary storage interface 316. The secondary storage devices and their associated computer-readable media provide non-volatile storage of computer-readable instructions (including application programs and program modules), data structures, and other data for computing device 300.

[0104] Although the exemplary environment described herein uses a hard disk drive as a secondary storage device, other types of computer readable storage media are used in other embodiments. Examples of these other types of computer readable storage media include magnetic cassettes, flash memory cards, digital video disks, Bernoulli cartridges, compact disk read only memory, digital versatile disk read only memory, random access memory, or read only memory. Some embodiments include non-transitory media.

[0105] A number of program modules may be stored in the secondary storage device 314 or in memory 304 , including an operating system 318 , one or more application programs 320 , other program modules 322 , and program data 324 .

[0106] In some embodiments, the computing device 300 includes input devices that allow a user to provide input to the computing device 300. Examples of input devices 326 include a keyboard 328, a pointer input device 330, a microphone 332, and a touch-sensitive display 340. Other embodiments include other input devices 326. The input devices are often connected to the processing device 302 via an input / output interface 338 coupled to the system bus 306. These input devices 326 can be connected by any number of input / output interfaces, such as a parallel port, a serial port, a game port, or a universal serial bus. Wireless communication between the input devices and the interface 338 is also possible, and in some possible embodiments includes infrared, BLUETOOTH wireless technology, WiFi technology (such as 802.11a / b / g / n), cellular, or other radio frequency communication systems.

[0107] In this exemplary embodiment, touch-sensitive display device 340 is also connected to system bus 306 via an interface, such as video adapter 342. Touch-sensitive display device 340 includes a touch sensor for receiving input from a user when the user touches the display. Such a sensor may be a capacitance sensor, a pressure sensor, or other touch sensor. The sensor detects not only contact with the display, but also the location of the contact and movement of the contact over time. For example, a user may move a finger or stylus across the screen to provide written input. The written input is evaluated and, in some embodiments, converted into text input.

[0108] In addition to the display device 340, the computing device 300 may include various other peripheral devices (not shown), such as speakers or printers.

[0109] The computing device 300 further includes a communication device 346 configured to establish communication over a network. In some embodiments, when used in a local area networking environment or a wide area networking environment (such as the Internet), the computing device 300 is typically connected to the network via a network interface, such as a wireless network interface 348. Other possible embodiments use other wired and / or wireless communication devices. For example, some embodiments of the computing device 300 include an Ethernet network interface or a modem for communicating over the network. In still other embodiments, the communication device 346 is capable of short-range wireless communication. Short-range wireless communication is one-way or two-way short- to medium-range wireless communication. The short-range wireless communication can be established according to various technologies and protocols. Examples of short-range wireless communication include radio frequency identification (RFID), near field communication (NFC), Bluetooth technology, and Wi-Fi technology.

[0110] Computing device 300 typically includes at least some form of computer-readable media. Computer-readable media includes any available media that can be accessed by computing device 300. By way of example, computer-readable media include computer-readable storage media and computer-readable communication media.

[0111] Computer-readable storage media include volatile and nonvolatile, removable and non-removable media implemented in any device configured to store information, such as computer-readable instructions, data structures, program modules, or other data. Computer-readable storage media include, but are not limited to, random access memory, read-only memory, electrically erasable programmable read-only memory, flash memory or other memory technology, compact disk read-only memory, digital versatile disk or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium that can be used to store the desired information and that can be accessed by the computing device 300.

[0112] Computer-readable communication media typically embodies computer-readable instructions, data structures, program modules, or other data in a modulated data signal, such as a carrier wave or other transport mechanism, and includes any information delivery media. The term "modulated data signal" refers to a signal that has one or more of its characteristics set or changed in such a manner as to encode information in the signal. By way of example, computer-readable communication media includes wired media, such as a wired network or direct-wired connection, and wireless media, such as acoustic, radio frequency, infrared and other wireless media. Combinations of any of the above are also included within the scope of computer-readable media.

[0113] As discussed above, a computing device typically includes at least some form of computer-readable media. Computer-readable media includes any available media that can be accessed by a computing device. By way of example, computer-readable media includes computer-readable storage media and computer-readable communication media.

[0114] The computer-implemented methods described herein are implemented by storing a set of instructions in the neuroregulator, the external programmer, and / or the external charger. In embodiments, a user may select parameters for the electrical signal therapy, and upon selection, selects a combination of electrical signal treatments for the therapy program.

[0115] 6, an exemplary method 400 of operating a therapy system 100 is shown. In operation 402, the system 100 generates a user interface configured to receive various inputs from a user, such as one or more parameters, a therapy program, a schedule, and any other information usable for system operation. In operation 404, the system 100 receives a user input of a therapy program via the user interface. As described herein, the system 100 is configured to provide multiple therapy programs, and a user can select one of the available therapy programs via the user interface. In operation 406, the system 100 receives a user input of one or more parameters that determine characteristics of the therapy program.

[0116] In operation 408, the system 100 generates electrical signals based on the selected parameters, which implement the therapy program selected by the user. In operation 410, it is determined whether the on-time has elapsed. If so (operation 410, "yes"), the system 100 stops the therapy program. If not (operation 410, "no"), the system 100 determines in operation 412 whether there is an input to change one or more of the parameters. If there is an input (operation 412, "yes"), the system 100 changes the parameters based on the input and continues with operation 408 and subsequent operations. If not (operation 412, "no"), the system 100 continues with operation 408 and subsequent operations.

[0117] 6, the system 100 receives and utilizes a number of parameters to generate various patterns of electrical signals for different therapy programs. Example parameters are described as follows:

[0118] The parameters selected by the user include the type of nerve or organ, hi an embodiment the type of nerve is selected from vagus nerve, anterior vagus nerve, posterior vagus nerve, hiatus of the posterior nerve, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof.

[0119] In embodiments, a user may select parameters featuring a high frequency signal or a high frequency low duty cycle signal to downregulate / block neural activity. A user may also select parameters featuring a low frequency stimulation signal to upregulate / stimulate neural activity. A user may select parameters to apply multiple electrical signals applied to multiple nerves or nerve branches / fibers independently and separately. A user may also select parameters to apply multiple electrical signals applied to multiple nerves or nerve branches / fibers simultaneously or synchronously, or to otherwise apply multiple signals in a coordinated manner.

[0120] Additional examples of neuroregulators, pulse generators, electrodes, biosensors, therapy programs, therapy schedules, electrical signal patterns, treatment parameters, and the like are described in US20210146136 and WO2020214982, the disclosures of which are incorporated by reference in their entireties.

[0121] In some aspects, the present disclosure provides methods of making or assembling the systems described herein for treating a condition associated with type 2 diabetes in a subject. In one example, a method includes: (1) connecting a first electrode to an implantable pulse generator and placing the first electrode on a first nerve or organ; (2) optionally connecting a second electrode to the implantable pulse generator and placing the second electrode on a second nerve or organ; (3) configuring a programmable therapy delivery module of the implantable pulse generator to deliver at least one therapy program including a first electrical signal therapy and optionally a second electrical signal therapy, where the first electrical signal therapy is configured to be applied to the first nerve or organ via the first electrode and the second electrical signal therapy is configured to be applied to the second nerve or organ via the second electrode, where the first and / or second electrical signals initiate nerve stimulation or nerve block, respectively; and (4) configuring a programmable storage and communication module of the external component to store the at least one therapy program and to communicate the at least one therapy program to the implantable pulse generator.

[0122] In some embodiments, the first and / or second electrical signals each have a frequency selected to initiate activity on the first and / or second target nerves or organs, respectively, wherein the activity is upregulation or downregulation of neural activity.

[0123] In some embodiments, the method further includes connecting a glucose sensor to the implantable pulse generator and monitoring or detecting a plasma glucose level of the subject using the glucose sensor.

[0124] In some embodiments, the method further includes configuring a communication system of the external component to communicate parameters of the at least one therapy program to an external communication device.

[0125] In some embodiments, the method further includes connecting a transmitter to the glucose sensor to communicate data generated by the glucose sensor to an external communication device.

[0126] In some embodiments, the first and / or second electrodes are placed on the nerve or organ via a laparoscopic approach.

[0127] method In some aspects, the disclosure provides methods of treating a subject for a condition associated with type 1 diabetes and / or type 2 diabetes.

[0128] It is noted that type 2 diabetes can also be found when patients have other diseases such as kidney failure, certain tumors, liver disease, hypothyroidism, inborn errors of metabolism, severe infections, reactive hypoglycemia, and a number of drugs, including alcohol use. The proposed device can help treat type 2 diabetes in patents with these conditions.

[0129] In some embodiments, the method comprises applying an intermittent (or continuous) electrical signal to a target nerve or target organ of a subject at a site with said electrical signal selected to upregulate and / or downregulate neural activity of the nerve or organ, and restoring normal or baseline neural activity upon cessation of said upregulation and / or downregulation. In embodiments, the method results in a decrease in insulin secretion and / or an increase in glucagon secretion, or both. In some embodiments, the method achieves an increase in glucose concentration in the treated subject. In some embodiments, the method further comprises administering to the subject a composition comprising an effective amount of an agent that increases glycemic control. In some embodiments, the electrical signal is applied to the nerve or organ by implanting a device or system as described herein.

[0130] In some embodiments, a method of treating a condition associated with type 2 diabetes in a subject in need of treatment includes applying an intermittent (or continuous) neural stimulation signal to a target nerve of a subject having a type 2 diabetes condition at a stimulation site that upregulates neural activity of the nerve, the neural stimulation signal being selected to restore neural activity of the nerve upon cessation of the stimulation.

[0131] In some embodiments, a method is provided for treating a patient with a combination therapy for type 2 diabetes comprising: a) applying an intermittent (or continuous) nerve stimulation signal to a target nerve of the patient multiple times per day and over multiple days, the stimulation signal being selected to upregulate afferent and / or efferent nerve activity of the nerve, and the stimulation being selected to restore nerve activity upon cessation of the stimulation signal; and b) applying an intermittent (or continuous) nerve block signal to the target nerve of the patient, the stimulation being selected to downregulate afferent and / or efferent nerve activity of the nerve, and nerve activity restoring upon cessation of the block signal.

[0132] In some embodiments, a method of achieving glucose regulation in a patient includes positioning an electrode on or near a vagus nerve branch and an anodal electrode in contact with adjacent tissue, implanting in the patient a neural stimulator coupled to the electrode, and applying electrical pulses to the vagus nerve branch having defined characteristics of amplitude, pulse width, frequency, and duty cycle, the defined characteristics being selected to improve glucose regulation or restoring the patient's glucose levels to normal or desired levels.

[0133] In some embodiments, the method includes applying an intermittent (or continuous) electrical signal to a target nerve or organ, the electrical signal being selected to upregulate or downregulate neural activity of the nerve or organ and restore neural activity of the nerve upon cessation of the signal, the electrical signal being selected to at least one of increase or modify the amount of glucagon, decrease or modify the amount of insulin, or increase glucose levels to reach or exceed a predetermined level. In some embodiments, the electrical signal is selected for frequency, pulse width, amplitude, and timing to upregulate neural activity as described herein. In some embodiments, the electrical signal is selected for frequency, pulse width, amplitude, and timing to downregulate neural activity as described herein. In some embodiments, the electrical signal is selected to increase or modify the release of glucagon and / or decrease or modify insulin by the pancreas, particularly when plasma glucose is below a predetermined threshold level. In some embodiments, the electrical signal is selected to modify liver sensitivity to glucagon.

[0134] In embodiments, the electrical signal is applied intermittently in a cycle that includes an on-time of application of the signal followed by an off-time during which the signal is not applied to the nerve, and the on-time and off-time are applied multiple times per day for multiple days. In some embodiments, the on-time is selected to have a duration of about 30 seconds to about 5 minutes. When the signal is selected to downregulate activity on the nerve, the electrical signal is applied at a frequency of about 200 Hz to about 10,000 Hz. When the signal is selected to upregulate activity on the nerve, the electrical signal is applied at a frequency of about 0.01 Hz to about 200 Hz.

[0135] In embodiments, the electrical signal is applied to an electrode positioned on the vagus nerve. In some cases, the electrical signal is applied on the hepatic branch of the vagus nerve. In other cases, the electrical signal is applied on the celiac branch of the vagus nerve. In some embodiments, the electrical signal is applied to an organ involved in glucose regulation, such as the liver, pancreas, duodenum, jejunum, or ileum.

[0136] In embodiments, both a downward control signal and an upward control signal are applied. In some cases, the signals are applied at the same time, at different times, or at overlapping times. In some embodiments, the downward control signal is applied to the vagus nerve near the liver and the upward control signal is applied to the vagus nerve near the pancreas. In some embodiments, the downward control signal is applied to the hepatic branch of the vagus nerve and the upward control signal is applied to the celiac branch of the vagus nerve.

[0137] In some embodiments, a method of treating a condition associated with type 2 diabetes in a subject comprises measuring plasma glucose levels after an intravenous (IV) glucose tolerance test (IVGTT) using ligation of the hepatic branch of the vagus nerve or high frequency alternating current (HFAC) blockade during stimulation of the celiac branch of the vagus nerve.

[0138] In some embodiments, the method further comprises detecting plasma glucose or glucagon or insulin levels to determine whether to apply electrical signal therapy. If plasma glucose and / or glucagon levels fall below expected normal or baseline levels in control samples from subjects with diabetes, therapy to increase glucagon and / or reduced insulin can be triggered until plasma glucose levels rise to expected levels required to maintain adequate control of type 2 diabetes. Such levels are known or can be determined using methods known to those skilled in the art.

[0139] In some embodiments, the method further comprises administering an amount of an agent, such as glucose, glucagon, or dextrose, to facilitate maintenance of type 2 diabetes.

[0140] In some embodiments, the method comprises applying a reversible intermittent (or continuous) modulatory signal to a target nerve or organ of a subject to down-regulate and / or up-regulate neural activity of the nerve.

[0141] In some cases, the nerves are nerves that serve one or more digestive organs, including, but not limited to, the vagus nerve, the celiac nerve, the hepatic branch of the vagus nerve, and the splanchnic nerves, and the applied signal may upregulate and / or downregulate neural activity of one or more of the nerves.

[0142] In some embodiments, the modulating signal includes applying an electrical signal. The signal is selected to upregulate or downregulate neural activity and allows recovery of neural activity upon cessation of the modulating signal. A pulse generator can be used to modulate the application of the signal to modify the characteristics of the signal to provide a reversible intermittent (or continuous) signal, as described above. The characteristics of the signal include the location of the signal, the frequency of the signal, the amplitude of the signal, the pulse width of the signal, and the administration cycle of the signal. In some embodiments, the signal characteristics are selected to provide for treating a condition associated with type 2 diabetes.

[0143] In embodiments of the methods described herein, a signal is applied to a target nerve at a site, the signal being selected to upregulate neural activity of the nerve, with neural activity recovering upon cessation of the signal. In some embodiments, an upcontrol signal may be applied to a first nerve or organ in combination with a downcontrol signal applied to a second nerve or organ to improve glucose regulation.

[0144] The signal is selected to upregulate neural activity and allow recovery of neural activity upon cessation of the signal. The pulse generator is used to modulate the application of the signal to modify the characteristics of the signal to provide a reversible intermittent (or continuous) signal, as described above. The characteristics of the signal include the frequency of the signal, the location of the signal, and the cycle of administration of the signal.

[0145] In some embodiments, the electrodes applied to the target nerve are energized with an up-control signal. The signal is applied for a limited time (e.g., 5 minutes). The speed of neural activity recovery varies from subject to subject. However, 20 minutes is a reasonable example of the time required to recover to baseline. After recovery, application of an up-signal again up-regulates neural activity, which can then recover after the cessation of the signal. Before full recovery, the signal can be applied anew. For example, the up-control signal can be updated after a limited time (e.g., 10 minutes).

[0146] In some embodiments, up-control signals may be applied in combination with down-control signals to improve glucose regulation, increase / modify the amount of glucagon secreted, decrease / modify the amount of insulin, and / or increase the amount of plasma glucose. Neuromodulation signals may affect the sensitivity of the liver to glucagon, the amount of glucose absorbed from food, and the amount of glucagon and / or insulin secreted from the pancreas. Neuromodulation results in a decrease in the amount of insulin required by the subject.

[0147] The up-control and down-control signals may be applied to different nerves at the same time, to the same nerve at different times, or to different nerves at different times. In embodiments, the up-control signal may be applied to the celiac nerve or the splanchnic nerve. In other embodiments, the up-control or down-control signal may be applied to the hepatic branch of the vagus nerve, or a signal may be applied to increase or control the amount of glucose secreted from the liver.

[0148] In some embodiments, the up-control signal is applied to a branch of the vagus nerve multiple times per day and over multiple days in combination with a down-control signal that is applied to a different nerve or organ intermittently multiple times per day and over multiple days. In some embodiments, the up-control signal is applied due to a sensed event, such as the presence of an amount of plasma glucose. In other embodiments, the up-control signal applied to the splanchnic or celiac nerve can be applied during a period of time that is typically 15-30 minutes after the subject's usual mealtime or after the time that plasma glucose levels decline.

[0149] In some cases, the signal is applied at a specific time. For example, a downward control signal may be applied before and during a meal, followed by a stimulation signal about 30-90 minutes after the meal. In another example, an upward control signal may be applied to the vagus nerve or the celiac branch of the vagus nerve late in the evening when glucose is declining.

[0150] In some embodiments, when the monitor detects low plasma glucose levels, a stimulation signal is applied to the celiac branch of the vagus nerve. In other embodiments, an inferior control signal is continuously delivered to the hepatic branch of the vagus nerve, or the ventral vagus trunk above the branch of the hepatic nerve, along with stimulation of the celiac branch, or the dorsal vagus trunk above the branch of the celiac nerve. However, if the internal monitor detects that plasma glucose has reached an undesirable hypoglycemic state, the blocking signal is stopped and stimulation continues alone.

[0151] Modulation of neural activity can be achieved by upregulating and / or downregulating neural activity of one or more target nerves or organs.

[0152] In some embodiments, the electrodes can be positioned at several different sites and locations on or near the target nerve. The target vagus nerve branch includes the celiac nerve, hepatic nerve, vagus nerve, splanchnic nerve, or some combination thereof, of the subject. The electrodes may also be positioned to apply signals to organs proximate to the vagus nerve, such as the liver, duodenum, jejunum, ileum, spleen, pancreas, esophagus, or stomach. In some embodiments, the electrodes are positioned to apply electrical signals to the nerve at a location distal to the subject's diaphragm.

[0153] Electrodes may be positioned on different nerves to apply downward control signals as opposed to upward control signals. For example, downward control signals may be applied to the hepatic nerve and upward control signals to the celiac nerve. In some embodiments, the signals may block the vagus nerve to the liver to reduce nerve-mediated reflex secretion and simultaneously or subsequently stimulate the peritoneal cavity to inhibit insulin secretion and / or upregulate the celiac nerve to stimulate glucagon production.

[0154] In some embodiments, the electrodes are positioned to apply signals to a branch or trunk of the vagus nerve. In other embodiments, the electrodes are positioned to apply signals to the ventral trunk, the dorsal trunk, or both. In some embodiments, the electrodes may be positioned on or near the same nerve, or at two different locations on the nerve and on a gastrointestinal organ.

[0155] In some embodiments, the lower control signal has a frequency of at least 200 Hz and up to 5000 Hz. In other embodiments, the signal is applied at a frequency of about 500-5000 Hz. In some embodiments, the lower control signal has a frequency of 3,000 Hz to 5,000 Hz or more when applied by two or more bipolar electrodes. Such signals have a preferred pulse width of 100 microseconds (associated with a frequency of 5,000 Hz). A short "off" time in the pulse cycle (e.g., between cycles or within a cycle) can be tolerated as long as it is short enough to avoid nerve repolarization. The waveform can be a square or sinusoidal waveform, or other shape. Higher frequencies of 5,000 Hz or more have been found to result in more consistent nerve conduction blocks in porcine studies. Preferably, the signal is bipolar, biphasic, delivered to two or more electrodes on the nerve.

[0156] In some embodiments, a signal amplitude of 0.01-20.0 mA is sufficient to block. In other embodiments, a signal amplitude of 0.01-10 mA is sufficient to block. In yet other embodiments, a signal amplitude of 0.01-8 mA is sufficient to block. Other amplitudes may be sufficient. Other signal attributes can be altered to reduce the likelihood of modulation by the nerve or organ. These include alterations in power, waveform, or pulse width.

[0157] The upregulation signal typically comprises a signal with a frequency of less than 200 Hz, more preferably 0.01-200 Hz, more preferably 10-50 Hz, more preferably 5-20 Hz, more preferably 5-10 Hz, more preferably 1-5 Hz, more preferably 0.1-2 Hz, and most preferably 1 Hz. Such a signal has a preferred pulse width of 0.1-10 microseconds. In some embodiments, a signal amplitude of 0.1-12 mA is sufficient to stimulate. Other amplitudes may be sufficient. Other signal attributes can be altered to reduce the likelihood of modulation by the nerve or organ. These include alterations in power, waveform, or pulse width.

[0158] Selection of signals that upregulate and / or downregulate neural activity and / or allow recovery of neural activity may involve selection of signal type and timing of signal application. For example, with electrode conduction block, block parameters (signal type and timing) may be altered by the pulse generator and coordinated with the stimulation signal. The exact signal to achieve block may vary from patient to patient and from nerve site to nerve site. The exact parameters may be individually tuned to achieve nerve conduction block at the block site.

[0159] In some embodiments, the signal has a duty cycle that includes an on-time during which the signal is applied to the nerve, followed by an off-time during which the signal is not applied to the nerve. For example, the on-time and off-time can be adjusted to allow for partial recovery of the nerve. In some cases, the down-control signal and the up-control signal can be adjusted such that the up-control signal is applied when the down-control signal is not applied, such as when the down-control signal is applied at a particular time or due to a sensed event. In some embodiments, the sensed event indicates that the up-control signal is applied and the down-control signal is not applied for a period of time associated with the sensed event, such as, for example, plasma glucose being below a certain threshold. In a preferred embodiment, the signal is applied continuously.

[0160] In some embodiments, the subject receives an implanted component 104. (FIG. 3) Electrodes 212, 212a are placed on the AVN and / or PVN just below the patient's diaphragm. An external antenna (coil 102) (or other communication system) is placed on the patient's skin overlying the implanted receiving coil 105. The external control unit 101 can be programmed for various signal parameters, including options for frequency selection, pulse amplitude, and duty cycle. For stimulating signals, frequencies below about 200 Hz are selected. For blocking signals, frequency options include about 200 Hz to about 5,000 Hz. Amplitude options are 0 to 10 mA.

[0161] In some embodiments, upcontrol signals may be applied in combination with downcontrol signals to improve glucose regulation.

[0162] Typically, patients use the device only while awake. The times of therapy delivery can be programmed into the device by the clinician (e.g., automatically on at 7 am and automatically off at 9 pm). In some cases, therapy times are modified to accommodate times when blood glucose levels fluctuate, such as before meals and 30-90 minutes after meals. For example, therapy times may be adjusted to start at 5 am before breakfast and end after 9 pm, depending on when the last meal or snack is consumed. In RF-powered versions of the pulse generator, device use is subject to patient control. For example, the patient may choose not to wear an external antenna. The device tracks usage by recording the times when the receiving antenna is coupled to the external antenna via radio frequency (RF) coupling through the patient's skin.

[0163] In some embodiments, the external component 101 can interrogate the pulse generator component 104 for various information. In some embodiments, a therapy time of between 30 seconds and 180 seconds per duty cycle is preferred over a therapy time of less than 30 seconds per duty cycle or more than 180 seconds per duty cycle.

[0164] During a 10 minute duty cycle (i.e., 5 minutes of intended therapy followed by 5 minutes of off-time), a patient can have multiple therapy onsets. For example, within any given 5 minutes of intended on-time, if a patient experiences 35 seconds of on-time and 1.5 minutes of actual on-time (the remainder of the 5 minutes of intended on-time is a period of no therapy due to signal interruption), the patient can have two actual therapy onsets even though only one was intended. The number of therapy onsets varies inversely with the length of on-time the patient experiences.

[0165] In some embodiments, sensors may be used. Sensing electrodes SE may be added to monitor neural activity as a way to determine how to adjust neural activity and / or duty cycle. The sensing electrodes may be additional electrodes to the stimulating electrodes, but it will be understood that a single electrode may perform both functions. The sensing electrodes and the stimulating electrodes may be connected to a controller as shown in FIG. 3. Such a controller is the same as the controller 102 described above with the added functionality of receiving signals from the sensing electrodes.

[0166] In some embodiments, the sensor may be a sensing electrode, a glucose sensor, or a sensor that senses other biomolecules or hormones of interest. When the sensing electrode SE produces a signal representative of the targeted minimum vagal activity or tone, the controller with the additional capability of receiving a signal from the sensing electrode energizes the stimulation electrode BE with an upregulation signal. As described with reference to the controller 102 (FIG. 3), the controller with the additional capability of receiving a signal from the sensing electrode can be remotely programmed with parameters of stimulation duration and no stimulation duration, as well as targets for initiating up or down control signals.

[0167] Ideal model species for testing the present invention include alloxan-treated glucose intolerant pigs and, to a lesser extent, Zucker obese rats. These models are ideal given the similarity of anatomy to humans and to patients with type 2 diabetes. Pigs have the added advantage of being similar in scale to human anatomy, especially as it relates to the vagus nerve. The anatomy of the vagus nerve pathway and associated organ systems is shown in Figure 1. Alloxan treatment induces type 2 diabetes pathology in the porcine model. Pigs were trained for 7 days prior to pre-implantation oral glucose testing to wear a jacket to accommodate two mobile chargers. During the charging sessions, the pigs were not restrained and there was no obvious stress to the animals. A future goal is the generation of a single implantable 5000Hz / stimulation device. In the porcine experiments, glycemic control was accessed by oral glucose tolerance testing during simultaneous hepatic branch occlusion and celiac branch stimulation. Insulin measurements were performed before and after the porcine experiments, which gives insight into beta cell depletion. In Zucker obese rat experiments, glycemic control was assessed by an intravenous glucose tolerance test during hepatic branch block with simultaneous peritoneal stimulation.

[0168] The present invention demonstrated increased glycemic control in animal models without significant tissue damage. Following the experiments, safety was evaluated using histopathological diagnosis of the brain, liver, pancreas and nerves. Current experiments suggest that stimulation and block can be used in combination with a continuous glucose monitoring device to blunt glucose spikes and manage type 2 diabetes. There is an opportunity to use stimulation and block as a closed-loop system with AI and machine learning tools to optimize type 2 diabetes therapy. These studies demonstrate that the present invention is safe and shows efficacy by blunting glucose spikes and achieving glycemic control.

[0169] FIG. 1 illustrates the relevant pathways of the vagus nerve below the diaphragm. The vagus nerve extends from the brainstem (not shown) and enters the abdominal cavity where it branches out, among others, from the hepatic and celiac branches. The hepatic branch inhibits the liver so that it releases glucose into the bloodstream. The disclosed treatment delivers electrical stimulation at a frequency of 5000 Hz to the hepatic branch, creating an electrical block and preventing stimulation of the liver. The celiac branch inhibits the pancreas and stimulates the release of insulin from the pancreas. The disclosed treatment delivers electrical stimulation at a frequency of 1 Hz to the celiac branch, stimulating the pancreas. Blocking the hepatic branch may reduce the liver's sensitivity to glucagon and has been shown to reduce insulin resistance by attenuating PPARα. Electrodes were fixed at the hepatic and celiac branching points. FIG. 2 illustrates the location of the electrodes relative to the abdominal anatomy. Stimulation of the celiac branch has been shown to increase plasma insulin and glucagon. FIG. 10 shows a blocking 5000 Hz waveform applied to the hepatic branch and a stimulating 1 Hz waveform applied to the celiac branch of the vagus nerve.

[0170] Testing in a type 2 diabetes rat model involved administration of intravenous glucose during experimental and control treatments. Figures 11 and 12 show the results of testing in the rat model. Figure 11 shows the mean % change in plasma glucose over time for rats in the experimental and sham treatment groups. Data acquired between 0 and 30 minutes shows the mean % change in plasma glucose during treatment. Data acquired between 50 and 80 minutes shows the mean % change in plasma glucose 15 minutes after cessation of treatment. Data at 45 minutes is the baseline blood glucose % change after cessation of intravenous glucose. As shown in Figure 12, the mean % change in plasma glucose for rats in the experimental group is compared to the sham and vagotomy + stimulation treatment groups.

[0171] In preparation, isolated nerve electrophysiology was performed to determine electrical energy parameters for stimulating and blocking the porcine subdiaphragmatic vagus nerve. Figures 13-16 show the types of tests that were performed to establish these parameters. Figure 13 shows that compound action potentials were evoked when the nerve was stimulated. Strength-duration curves were constructed to determine the nerve's excitability and stimulation parameters, as shown in Figure 14. Results of the 5000 Hz block experiment, shown in Figure 15, demonstrated that 8 mA was the optimal current amplitude for the block, and it took approximately 15 minutes to recover after the block, as seen in Figure 16. The same parameters used in the isolated porcine vagus nerve experiment were used in the in vivo study.

[0172] To confirm that the pig model is suitable for testing the present invention, glucose tolerance and insulin response were tested. Figures 17 and 18 show the results of these tests, illustrating the suitability of the model of the present invention. The glucose curve shown in Figure 17 indicates glucose intolerance, while the reduced insulin production shown in Figure 18 indicates a suitable response to alloxan. Thus, the pigs are not insulin dependent and some pancreatic function was preserved, indicative of type 2 diabetes.

[0173] Figures 19 and 20 relate to studies performed in a type 2 diabetes porcine model in which glucose was administered orally. Figure 19 shows the mean % change in blood glucose levels over time in porcine subjects before and after implantation of electrodes. Figure 20 shows the mean % change in blood glucose levels over time in porcine subjects undergoing experimental or sham treatment. Figure 21 shows HFAC+ stimulation in alloxan-treated pigs. Titrating doses of alloxan-induced partial ablation of beta cells were utilized. After alloxan treatment, pigs had reduced glycemic control, but not insulin-dependent. IVGTT was performed before and after alloxan treatment, which showed a significant increase in AUC after alloxan (pre-alloxan AUC=3237±362AU, post-alloxan AUC=7230±483AU, p<0.001, Student's t-test). After recovery from IVGTT, PG was 113±9. The HFAC and the anodal and cathodal electrodes delivering the stimulation were of the same size, configuration, separation and impedance (typically 1000 ohms) as used in the associated vagus nerve electrophysiology study. Figure 22 shows the fluctuations in blood glucose in porcine subjects over the course of experimental treatment versus sham treatment. Figure 23 shows the mean change in plasma glucose in porcine subjects receiving intermittent experimental treatment (30 min) compared to subjects receiving prolonged experimental treatment (240 min) or sham treatment.

[0174] FIG. 24 shows the results of histopathological examination on brain, liver, pancreas, and nerve tissues, respectively, after experimental treatment. Findings were normal in the brain, liver, pancreas, and nerves. Apoptosis in the pancreatic islets was observed, which was consistent with alloxan treatment and similar to findings observed in the control group of alloxan-treated pigs that did not receive block and stimulation signals. Histopathological examination of brain, liver, and pancreatic tissues showed that they were healthy after the experiment was stopped. All vagus nerve fibers and constituent axons within the cuff space were morphologically normal. There was no evidence of tissue damage at the electrode contact on the cuff with the vagus nerve. EXAMPLES

[0175] Example 1 - Implantable HVNS System Certain exemplary systems are described in accordance with the present disclosure. FIG. 7 shows the individual components of an exemplary HVNS system. In the illustrated example, the implantable HVNS system includes a rechargeable neuromodulator (RNR) pulse generator in combination with a Guardian™ Connect CGM system for glucose monitoring glucose. The HVNS system further includes two electrical leads with platinum-iridium electrodes that connect to the rechargeable neuromodulator (RNR) implantable pulse generator, and a transmitting coil positioned on the RNR, outside the skin layer, and communicating with the RNR via an antenna using a 6.73 MHz radio frequency signal. The signal from the coil is used to program the stimulation parameters as well as charge the RNR. A portable charger (MC) is connected to the transmitting coil for charging and programming, and to a clinician programmer that is connected to the MC for programming the stimulation parameters. The portable charger is charged when connected to an AC charger. The Guardian™ Connect system includes a sensor inserted under the skin to measure glucose in interstitial fluid. A transmitter is connected to the sensor, and this information is transmitted to the transmitter. The transmitter then wirelessly transmits this data via blue-tooth technology to a smart device (e.g., an iPhone® or iPad®), which displays the plasma glucose level.

[0176] With reference to Figures 8-9, the HVNS system includes a pulse generator, a lead placed on the vagus nerve, and an implantable glucose sensor (for monitoring plasma glucose levels). The sensor sampling rate is approximately 1 second to 10 minutes. Figure 8 shows a schematic diagram of the system where the implantable glucose sensor communicates with the pulse generator to initiate vagus nerve stimulation. The implantable sensor detects low plasma glucose levels and sends a signal to turn on the pulse generator. Figure 9 shows a schematic diagram of the system where the implantable glucose sensor first communicates with an external device attached to the outside of the skin, and then communicates with the pulse generator to initiate vagus nerve stimulation.

[0177] The communication between the pulse generator and the glucose sensor can be via, but is not limited to, blue tooth technology, radio frequency, WIFI, light or sound. In some embodiments, the glucose sensor is under a layer of skin and communicates to a device outside the skin using a battery to power the wireless communication. The communication between the glucose sensor and a device outside the body can be via, but is not limited to, blue tooth technology, radio frequency, WIFI, light or sound. Thus, the device outside the skin communicates with the pulse generator through, but is not limited to, blue tooth technology, radio frequency, WIFI, light or sound. The implantable glucose sensor, or an external device communicating with the implantable glucose sensor, can also communicate with a smart device (such as a phone running an app) to display the plasma glucose level and send an alarm when the plasma glucose reaches an unsafe low level. The communication to the smart device can be via, but is not limited to, blue tooth technology, radio frequency, WIFI, light or sound. Stimulation parameters include a frequency range of 0.01 Hz to 200 Hz, a current or voltage amplitude range of 0.1 mA to 12 mA or 0.1 to 12 volts, and a pulse width range of 0.1 ms to 10 ms. Stimulation can be continuous or bursts with burst intervals ranging from milliseconds, seconds to minutes.

[0178] Stimulation sites include any segment of the vagus nerve, including the anterior or posterior vagus trunk below the diaphragm, and branches of the anterior vagus trunk, such as the celiac branch from the posterior vagus trunk, the paraceliac branch from the anterior vagus trunk, or the hepatic branch from the anterior vagus trunk. Stimulation sites also include the anterior or posterior thoracic vagus nerve, or the left or right cervical vagus nerve. Any combination of vagus nerve stimulation sites is included.

[0179] In other embodiments, the HVNS system is fully closed loop with the primary cell RNR incorporating blue-tooth capability to communicate directly with the glucose transmitter. Low duty cycle on-demand stimulation can facilitate the use of small primary cell devices without the need for charging. The CGM transmitter can communicate with smart devices, allowing physicians to optimize therapy parameters during controlled type 2 diabetes trials.

[0180] Example 2 To make a comparison between the pig and rat models, the glucose changes were normalized to baseline glucose. In pigs, baseline glucose was measured 10 min before the oral glucose tolerance test, and in rats, baseline glucose was measured 5 min before the intravenous glucose tolerance test. For each species, in addition to the experimental tests, four sets of control experiments were performed: sham surgery, positive control vagotomy, stimulation alone, and vagotomy + stimulation. Data from the positive control vagotomy group and the stimulation alone group are excluded because the results of those treatments were not significantly different from the sham treatment. The results are shown in Figures 11-12 and 14-22. In our rat study, ligation of the hepatic branch did not increase glycemic control after the IVGTT. Anesthesia may affect PG. In the study, there was a 10-day period after surgery before the OGTT experiment was performed, and the post-implant OGTT produced a similar response to the pre-implant OGTT. It is unlikely that anesthesia significantly affected the results of this study. The increased glycemic control observed with blockade and stimulation applied 5 min after the start of an oral glucose tolerance test provided inspiration for our methodology, which works using continuous glucose monitoring technology to blunt glucose spikes on demand.

[0181] As shown in FIG. 11, the initial plasma glucose of rats increased by an average of 63±12% 5 minutes after glucose administration in the sham group and remained elevated for 30 minutes with partial recovery. The area under the curve (AUC) for the sham group was equal to 1543±257. In this experimental group, the initial % change in plasma glucose did not increase rapidly, and in the sham group, the AUC decreased significantly (AUC=898±68, p<0.05). After 30 minutes, treatment was stopped. The baseline % change in plasma glucose was measured 15 minutes after cessation of treatment, and intravenous glucose was administered again without treatment. Plasma glucose increased in both the sham and experimental treatments, followed by a slight decrease over the course of 30 minutes. Despite a slightly attenuated response in the experimental group, both groups showed a similar trend, suggesting functional recovery after cessation of experimental treatment. This recovery makes the present invention advantageous over previous treatment methods, as it allows greater control of the treatment by the physician and reduces the possibility of developing resistance to the treatment, as seen in vagotomy treatments.

[0182] FIG. 12 shows the % change in plasma glucose in the experimental group compared to two control groups: sham and vagotomy + stimulation treatment. As can be seen, the differences between the experimental and sham groups are similar to those of the initial study shown in FIG. 11. More importantly, FIG. 12 shows similar activity in % change between the experimental and vagotomy + stimulation treatments. This data supports an effective electrical blockade in the hepatic branch, comparable to that of vagotomy, but with the advantage of the aforementioned controls and reduced chance of resistance to the treatment.

[0183] Figure 19 shows no significant change in the ability to process plasma glucose as a result of surgery, eliminating the implant as a potential source of variation in porcine subjects. Figure 20 shows the percent change in plasma glucose over 240 minutes after administration of oral glucose in the experimental and sham treatment groups. The mean AUC in the sham treatment group was 6228±1293. The experimental treatment group showed a significant decrease in AUC compared to the sham treatment group of 2225±825, p=0.015, demonstrating the efficacy of the invention not only in the rat model, but also in the pig. This is a promising development, suggesting efficacy in human patients given the similar anatomy and physiology of the model species.

[0184] Example 3 The experiment carried out in Example 2 demonstrated an increase in mean glycemic control as a result of the present invention, but did not take into account the variation in plasma glucose between test subjects. The experimental design was similar to the pig study in Example 2, and in the experimental group, the abdominal fibers were stimulated at a frequency of 1 Hz with a high-frequency alternating current (5000 Hz) interruption applied simultaneously to the liver fibers. A sham-treated control was also used to compare the results. The results of the experiment are shown in Figure 21.

[0185] The sham treatment group showed a high level of variability with a standard deviation of 62±11 mg / dL and a coefficient of variation of 38±6%. The experimental treatment group showed a significant reduction in variability with a standard deviation of 13±1 mg / dL (p<0.01) and a coefficient of variation of 17±2% (p<0.01). This finding is important because large PG variability has been shown to increase oxidative stress, leading to comorbidities in type 2 diabetes. This data demonstrates that the present invention not only results in increased glycemic control, but also reduces potentially dangerous plasma glucose spikes.

[0186] Example 4 In the above experiments, block and stimulation were delivered for the entire 4-hour glucose tolerance test, which used a significant amount of energy. This prompted exploration intermittent block and stimulation to maintain glycemic control by applying signals only for the first 30 minutes of the glucose tolerance test in alloxan-induced type 2 diabetic pigs. Glycemic control was assessed using an oral glucose tolerance test (OGTT) in alloxan-treated pigs.

[0187] In the above experiments, simultaneous stimulation and electrical blockade were applied for extended periods of time. To limit energy expenditure, the effectiveness of a shorter treatment duration (30 min) was tested compared to a longer treatment (240 min). The results of the experiment are shown in FIG. 22.

[0188] Example 5 Although the above examples have demonstrated the efficacy of the present invention, safety issues remain a concern. Conventional vagotomy causes significant and irreversible tissue damage, but the present invention shows that the damage to the involved tissues is significantly reduced. Tissue damage was assessed by histopathology of tissue samples taken from porcine subjects. The results are shown in Figure 23.

[0189] Following the experiment, brain, liver, pancreas, and nerve histopathology were used to demonstrate safety. The arrowheads seen in the brain histopathology (scale bar: 100 μM) are an increase in clear spaces surrounding the vasculature, and the arrows point to shrinking basophilic cells surrounded by clear spaces. These findings are common artifactual changes. In the liver (scale bar: 20 μM), mild bile duct hyperplasia is indicated by the black arrows. There is mild diffuse aqueous change, but it is not clinically relevant. The circles shown in the pancreas histopathology (scale bar: 20 μM) surround the pancreatic islets. The black arrows indicate apoptotic cells similar to the unstimulated control, which is expected after diabetes induction with alloxan-inducing treatment. In the vagus nerve histopathology, there was no evidence of tissue damage at the electrode contact on the cuff with the vagus nerve (scale bar: 500 μM). The host reaction to the cuff sheath and surgical fixation site was typical for the animal model at the time point after implantation. These findings are significant because they give the present invention an advantage over conventional vagotomy, which causes irreversible damage to the hepatic branch of the vagus nerve and loses effectiveness over time as the patient becomes resistant to the treatment. By preserving healthy nerve tissue, the disclosed treatments can be utilized as needed.

[0190] The following numbered clauses define further exemplary aspects and features of the present disclosure. 1. A system for treating diabetes in a subject, comprising: a first electrode positioned on a first nerve or organ and adapted to deliver an electrical signal to the first nerve or organ; Optionally, a second electrode disposed on a second nerve or organ and adapted to deliver an electrical signal to the second nerve or organ; a pulse generator operably connected to the first and / or second electrodes, the pulse generator comprising a power module and a programmable therapy delivery module, the programmable therapy delivery module configured to deliver at least one therapy program including a first therapy program and optionally a second therapy program, the first therapy program including a first electrical signal treatment applied via the first electrode to a first nerve or organ, the second therapy program including a second electrical signal treatment applied via the second electrode to a second nerve or organ, the first and / or second electrical signals each configured to initiate an activity on the first and / or second nerve or organ, respectively, the activity being nerve stimulation or nerve block; and an external component including a communications system and a programmable storage and communications module, the programmable storage and communications module configured to store at least one therapy program and communicate the at least one therapy program to a pulse generator. 2. The system of clause 1, wherein the first and / or second electrical signals are each independently configured to upregulate or downregulate activity on the first and / or second target nerves or organs, respectively. 3. The system of clause 1 or 2, wherein the first and second electrical signals are applied simultaneously, synchronously, intermittently, during substantially the same time, during substantially different times, or in a coordinated manner. 4. The system of any one of clauses 1 to 3, wherein the first and / or second electrical signal treatments are applied sequentially, respectively, to a first target nerve or organ and / or a second target nerve or organ. 5. The system of any one of clauses 1 to 4, further comprising a glucose sensor configured to continuously monitor plasma glucose of the subject, the glucose sensor operably connected to the pulse generator and the external component. 6. A system described in any one of clauses 1 to 5, wherein the glucose sensor is configured to detect an increase or decrease in plasma glucose from a predetermined threshold level. 7. The system of clause 6, wherein the pulse generator is triggered to deliver the first and / or second electrical therapies when the subject's plasma glucose is below a first predetermined threshold, and the pulse generator stops delivering the first and / or second electrical therapies when the subject's plasma glucose is above a second predetermined threshold. 8. The system of any one of clauses 1-7, wherein the first nerve or organ and the second nerve or organ are each independently selected from the group consisting of the vagus nerve, anterior vagus nerve, posterior vagus nerve, hiatus of the posterior nerve, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof. 9. The system of any one of clauses 1 to 8, wherein the first and / or second electrical signals each have an on-time and an off-time, the off-time being selected to allow at least partial recovery of activity of the first and / or second nerve or organ. 10. The system of clause 9, wherein the on-time is configured to initiate upon detection of a plasma glucose level of 50 mg / dL and 90 mg / dL, or below 90 mg / dL, below 80 mg / dL, below 70 mg / dL, below 60 mg / dL, or below 50 mg / dL. 11. The system of any one of clauses 1-10, wherein the first and / or second electrical signal treatments are configured to change the plasma glucose level by at least about 5 mg / dL in about 10 minutes. 12. The system of any one of clauses 1-11, wherein the first and / or second electrical signal treatments are configured to change the plasma glucose level by at least about 10 mg / dL in about 20 minutes. 13. The system of any one of clauses 1-12, wherein the first and / or second electrical signal treatments are configured to change the plasma glucose level by at least about 20 mg / dL in about 30 minutes. 14. The system of any one of clauses 1 to 13, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz. 15. A system described in any one of clauses 1 to 13, wherein the first electrical signal has a frequency of about 200 Hz to about 10 kHz. 16. The system of any one of clauses 1 to 15, wherein the second electrical signal has a frequency of about 0.01 Hz to about 200 Hz. 17. The system of any one of clauses 1 to 15, wherein the second electrical signal has a frequency of about 200 Hz to about 10 kHz. 18. A system described in any one of clauses 1 to 13, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz and the second electrical signal has a frequency of about 200 Hz to about 10 kHz. 19. The system of any one of clauses 1-18, wherein the first electrical signal and / or the second electrical signal each independently include a signal pattern, each signal pattern including a pulse having a pulse width of about 0.1 microseconds to about 10,000 microseconds. 20. A system according to any one of clauses 1 to 19, wherein the pulses of the first and / or second electrical signals are monophasic pulses, or biphasic pulses, or a combination thereof. 21. The system of any one of clauses 1-20, wherein the first and / or second electrical signals each independently have an on-time of from about 30 seconds to about 30 minutes. 22. The system of any one of clauses 1-21, wherein the first and / or second electrical signals each independently have a current amplitude in the range of about 0.01 mAmps to about 20 mAmps. 23. The system of any one of clauses 1-22, wherein the first and / or second electrical signal each independently comprises a sudden onset of a pulse, or an increase in current / voltage amplitude, or an increase in frequency, or an increase in pulse width, or a combination thereof, at or near the start of application of the first and / or second electrical signal. 24. The system of any one of clauses 1-23, wherein the first and / or second electrical signal treatments are configured to be applied intermittently multiple times per day and over multiple days, and the first and / or second electrical signals each have a frequency selected to upregulate activity on the first nerve or organ and have an on-time and an off-time, the off-time selected to allow at least partial recovery of activity of the first nerve or organ. 25. A system described in any one of clauses 1 to 24, wherein the programmable storage and communication module is configured to store and communicate two or more therapy programs, each therapy program being different from the others and configured to be selected for communication. 26. The system of any one of clauses 1 to 25, further comprising a transmitter operably connected to the glucose sensor, the transmitter configured to communicate data generated by the glucose sensor to an external communication device. 27. A system described in any one of clauses 1 to 26, wherein the communication system is selected from the group consisting of antenna, blue tooth technology, radio frequency, WIFI, light, sound, and combinations thereof, and the communication system is configured to communicate parameters of at least one therapy program to an external communication device. 28. A method of treating type 2 diabetes in a subject, comprising: applying a first electrical signal to a first nerve or organ of a subject using the system of clause 1, the first electrical signal initiating nerve stimulation or a nerve block; Optionally, the method includes applying a second electrical signal to a second nerve or organ of the subject using the system described in clause 1, where the second electrical signal initiates nerve stimulation or nerve block. 29. The method of clause 28, wherein the first and second electrical signals are applied simultaneously, synchronously, intermittently, during substantially the same time, during substantially different times, or in a coordinated manner. 30. The method of clause 28 or 29, wherein the first and / or second electrical signal is configured to increase plasma glucose in the subject by at least about 5 mg / dL in about 10 minutes. 31. The method of any one of clauses 28-30, wherein the first and / or second electrical signal treatments are configured to change the plasma glucose level by at least about 10 mg / dL in about 20 minutes. 32. The system of any one of clauses 28-31, wherein the first and / or second electrical signal treatments are configured to change the plasma glucose level by at least about 20 mg / dL in about 30 minutes. 33. A method according to any one of clauses 28 to 32, wherein the first and / or second electrical signals are each applied continuously during an on-time followed by an off-time during which no signal is applied to the nerve or organ. 34. The method of any one of clauses 28 to 33, wherein the on-time is applied multiple times per day when the plasma glucose level is about 50 mg / dL, about 60 mg / dL, about 70 mg / dL, or about 80 mg / dL. 35. The method of any one of clauses 28-34, wherein the off-time is applied multiple times per day when the plasma glucose level is greater than about 80 mg / dL to about 90 mg / dL, or greater than about 100 mg / dL, or greater than about 110 mg / dL. 36. The method of any one of clauses 28 to 35, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz. 37. The method of any one of clauses 28 to 35, wherein the first electrical signal has a frequency of about 200 Hz to about 10 kHz. 38. The method of any one of clauses 28 to 37, wherein the second electrical signal has a frequency of about 0.01 Hz to about 200 Hz. 39. The method of any one of clauses 28 to 37, wherein the second electrical signal has a frequency of about 200 Hz to about 10 kHz. 40. The method of any one of clauses 28 to 35, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz and the second electrical signal has a frequency of about 200 Hz to about 10 kHz. 41. The method of any one of clauses 28-40, wherein the first nerve or organ and the second nerve or organ are independently selected from the group consisting of the vagus nerve, anterior vagus nerve, posterior vagus nerve, hiatus of the posterior nerve, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof. 42. The method of any one of clauses 28 to 41, wherein the first nerve or organ and the second nerve or organ are different. 43. The method of any one of clauses 28 to 42, wherein the first electrical signal is applied to a hepatic branch of the vagus nerve or abdominal vagus nerve centered at the bifurcation of the hepatic nerve. 44. The method of any one of clauses 28 to 42, wherein the first electrical signal is applied to the vagus nerve or the celiac branch of the abdominal vagus nerve, centered at the bifurcation of the celiac nerve. 45. The method of any one of clauses 28-42, wherein the first electrical signal is applied to the liver, the pancreas, or both. 46. ​​The method of any one of clauses 28 to 45, wherein the second electrical signal is applied to a splanchnic nerve, or the celiac branch of the vagus nerve, or the pancreas. 47. The method of any one of clauses 28 to 45, wherein the second electrical signal is not involved in the method. 48. The method of any one of clauses 28-47, further comprising administering an agent that improves glucose control. 49. The method of clause 48, wherein the agent reduces the amount of insulin and / or reduces the sensitivity of the cells to insulin. 50. A method of making a system for treating type 2 diabetes in a subject, comprising: connecting a first electrode to a pulse generator and placing the first electrode on a first nerve or organ; Optionally, connecting a second electrode to the pulse generator and placing the second electrode on a second nerve or organ; configuring a programmable therapy delivery module of the pulse generator to deliver at least one therapy program including a first electrical signal therapy and optionally a second electrical signal therapy, the first electrical signal therapy being configured to be applied to a first nerve or organ via a first electrode and the second electrical signal therapy being configured to be applied to a second nerve or organ via a second electrode, the first and / or second electrical signals initiating nerve stimulation or nerve block, respectively; and configuring a programmable storage and communications module of an external component to store at least one therapy program and to communicate the at least one therapy program to a pulse generator. 51. The method of clause 50, wherein the first and / or second electrical signals each have a frequency selected to initiate activity on a first and / or second target nerve or organ, respectively, and the activity is upregulation or downregulation of neural activity. 52. The method of clause 50 or 51, further comprising connecting a glucose sensor to the pulse generator and using the glucose sensor to monitor or detect plasma glucose levels in the subject. 53. The method of any one of clauses 50-52, further comprising configuring a communication system of the external component to communicate at least one parameter of the therapy program to an external communication device. 54. The method of any one of clauses 50-53, further comprising connecting a transmitter to the glucose sensor to communicate data generated by the glucose sensor to an external communication device. 55. The method of any one of clauses 50 to 54, wherein the first and / or second electrodes are positioned on the nerve or organ via a laparoscopic approach. 56. A system for treating diabetes in a subject, comprising: at least one electrode positioned on a nerve or organ of the subject and adapted to deliver an electrical signal to the nerve or organ of the subject; a pulse generator operably connected to the at least one electrode, the pulse generator comprising a power module and a programmable therapy delivery module, the programmable therapy delivery module configured to deliver at least one therapy program, the at least one therapy program including at least one electrical signal therapy applied to a nerve or organ via the at least one electrode; an external component including a communication system and a programmable storage and communication module, the programmable storage and communication module configured to store at least one therapy program and to communicate the at least one therapy program to the pulse generator; a glucose sensor operatively and communicatively connected to the pulse generator and to the external component, the glucose sensor configured to continuously monitor plasma glucose of the subject and to detect an increase or decrease in plasma glucose from a predetermined threshold level; the pulse generator is triggered to deliver the at least one electrical signal therapy when the subject's plasma glucose is at or below a first predetermined threshold, and the pulse generator stops delivering the at least one electrical signal therapy when the subject's plasma glucose is at or above a second predetermined threshold; The system, wherein at least one electrical signal therapy is configured to initiate neural stimulation to a target nerve or organ. 57. The system of clause 56, wherein the nerve or organ is selected from the group consisting of the vagus nerve, anterior vagus nerve, posterior vagus nerve, hiatus of the posterior nerve, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof. 58. The system of clause 56 or 57, wherein the nerve is the subject's posterior vagus nerve (PVN), or the celiac vagus branch of the PVN. 59. A system described in any one of clauses 56 to 58, wherein the electrical signal has an on-time and an off-time, the off-time being selected to allow at least partial recovery of nerve or organ activity. 60. The system of clause 59, wherein the on-time is configured to initiate upon detection of a plasma glucose level in the subject of about 50 mg / dL or less, about 60 mg / dL or less, about 70 mg / dL or less, or about 80 mg / dL or less. 61. The system of clause 59 or 60, wherein the on-time is from about 30 seconds to about 30 minutes. 62. The system of any one of clauses 56 to 61, wherein at least one electrical signal treatment includes an electrical signal pattern having a frequency of about 1 Hz to about 200 Hz, or about 1 Hz to about 50 Hz, or about 1 Hz to about 20 Hz, or about 1 Hz to about 10 Hz, or about 1 Hz to about 5 Hz, or about 1 Hz to about 2 Hz. 63. A system described in any one of clauses 56 to 62, wherein the electrical signal pattern has a pulse width of about 0.1 microseconds to about 10 microseconds in steps of about 0.1 microseconds. 64. A system described in any one of clauses 56 to 63, wherein the electrical signal pattern has a pulse amplitude of about 0.1 mA to about 12 mA, in steps of about 0.1 mA. 65. A system described in any one of clauses 56 to 64, wherein the pulse of at least one electrical signal is a monophasic pulse, or a biphasic pulse, or a combination thereof. 66. The system of any one of clauses 56-65, wherein at least one electrical signal further comprises a sudden onset of a pulse, or an increase in current / voltage amplitude, or an increase in frequency, or an increase in pulse width, or a combination thereof, at or near the start of application of the electrical signal. 67. A system described in any one of clauses 56 to 66, wherein at least one electrical signal treatment is configured to be applied multiple times per day and intermittently over multiple days. 68. The system of any one of clauses 56-67, wherein at least one electrical signal treatment is configured to increase the subject's plasma glucose by at least about 5 mg / dL in about 10 minutes, or at least about 10 mg / dL in about 20 minutes, at least about 20 mg / dL in about 30 minutes, or at least about 30 mg / dL in about 45 minutes, or at least about 40 mg / dL in about 60 minutes. 69. A system described in any one of clauses 56 to 68, wherein at least one electrical signal treatment is configured to cause an increase in insulin secretion in the subject. 70. The system of any one of clauses 56-69, wherein application of at least one electrical signal treatment is configured to cause a decrease in insulin secretion in the subject. 71. The system of any one of clauses 56 to 70, further comprising a transmitter operably connected to the glucose sensor, the transmitter configured to communicate data generated by the glucose sensor to an external communication device. 72. A system described in any one of clauses 1 to 71, wherein the communication system is selected from the group consisting of antenna, blue tooth technology, radio frequency, WIFI, light, sound, and combinations thereof, and the communication system is configured to communicate parameters of at least 56 therapy programs to an external communication device. 73. A method of treating type 2 diabetes in a subject in need thereof, comprising: A method comprising applying at least one electrical signal treatment to a subject's posterior vagus nerve (PVN) or a celiac vagus branch of the subject's PVN using a system described in any one of clauses 56 to 72. 74. The method of claim 73, wherein the electrical signal pattern applied to the has a frequency of about 1 Hz to about 20 Hz, a pulse width of about 0.1 microseconds to about 10 microseconds in steps of about 0.1 microseconds, and a pulse amplitude of about 0.1 mA to about 12 mA in steps of about 0.1 mA. 75. The method of clause 73 or 74, wherein application of the at least one electrical signal therapy increases the subject's plasma glucose by at least about 5 mg / dL, at least about 10 mg / dL, at least about 20 mg / dL, at least about 30 mg / dL, at least about 40 mg / dL, at least about 50 mg / dL, at least about 60 mg / dL, at least about 70 mg / dL, at least about 80 mg / dL, at least about 90 mg / dL, or at least about 100 mg / dL in about 60 minutes. 76. The method of any one of clauses 73-75, wherein application of at least one electrical signal treatment causes an increase in insulin secretion in the subject. 77. The method of any one of clauses 73-76, wherein application of at least one electrical signal treatment causes a decrease in insulin secretion in the subject. 78. The method of any one of clauses 73-77, further comprising placing at least one electrode on the nerve or organ via a laparoscopic approach. The above specification, examples, and data provide a complete description of the manufacture and use of the composition of the invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended.

Claims

1. 1. A system for treating diabetes in a subject, comprising: a first electrode positioned on a first nerve or organ and adapted to deliver an electrical signal to the first nerve or organ; Optionally, a second electrode disposed on a second nerve or organ and adapted to deliver an electrical signal to said second nerve or organ; a pulse generator operably connected to the first and / or second electrodes, the pulse generator comprising a power module and a programmable therapy delivery module, the programmable therapy delivery module configured to deliver at least one therapy program including a first therapy program and optionally a second therapy program, the first therapy program including a first electrical signal therapy applied via the first electrode to the first nerve or organ, the second therapy program including a second electrical signal therapy applied via the second electrode to the second nerve or organ, the first and / or second electrical signals each configured to initiate an activity on the first and / or second nerve or organ, respectively, the activity being nerve stimulation or nerve block; and an external component including a communications system and a programmable storage and communications module, the programmable storage and communications module configured to store the at least one therapy program and to communicate the at least one therapy program to the pulse generator.

2. 2. The system of claim 1, wherein the first and / or second electrical signals are each independently configured to upregulate or downregulate activity on the first and / or second target nerves or organs, respectively.

3. 3. The system of claim 1 or 2, wherein the first and second electrical signals are applied simultaneously, synchronously, intermittently, during substantially the same time, during substantially different times, or in a coordinated manner.

4. 4. The system of claim 1, wherein the first and / or second electrical signal therapies are each applied sequentially to the first target nerve or organ and / or the second target nerve or organ, respectively.

5. 5. The system of claim 1, further comprising a glucose sensor configured to continuously monitor plasma glucose of the subject, the glucose sensor operatively connected to the pulse generator and the external component.

6. The system of any one of claims 1 to 5, wherein the glucose sensor is configured to detect an increase or decrease in plasma glucose from a predetermined threshold level.

7. 7. The system of claim 6, wherein the pulse generator is triggered to deliver the first and / or second electrical therapies when the subject's plasma glucose is below a first predetermined threshold, and the pulse generator stops delivering the first and / or second electrical therapies when the subject's plasma glucose is above a second predetermined threshold.

8. 8. The system of claim 1, wherein the first nerve or organ and the second nerve or organ are each independently selected from the group consisting of the vagus nerve, anterior vagus nerve, posterior vagus nerve, posterior nerve hiatus, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof.

9. 9. The system of claim 1, wherein the first and / or second electrical signals each have an on-time and an off-time, the off-time being selected to allow at least partial recovery of the activity of the first and / or second nerves or organs.

10. 10. The system of claim 9, wherein the on-time is configured to initiate upon the detection of a plasma glucose level below 50 mg / dL and 90 mg / dL, or below 90 mg / dL, below 80 mg / dL, below 70 mg / dL, below 60 mg / dL, or below 50 mg / dL.

11. 11. The system of any one of claims 1 to 10, wherein the first and / or second electrical signal therapies are configured to change the plasma glucose level by at least about 5 mg / dL in about 10 minutes.

12. 12. The system of any one of claims 1 to 11, wherein the first and / or second electrical signal therapies are configured to change the plasma glucose level by at least about 10 mg / dL in about 20 minutes.

13. 13. The system of any one of claims 1 to 12, wherein the first and / or second electrical signal therapies are configured to change the plasma glucose level by at least about 20 mg / dL in about 30 minutes.

14. The system of any one of claims 1 to 13, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz.

15. The system of any one of claims 1 to 13, wherein the first electrical signal has a frequency of about 200 Hz to about 10 kHz.

16. The system of any one of claims 1 to 15, wherein the second electrical signal has a frequency of about 0.01 Hz to about 200 Hz.

17. The system of any one of claims 1 to 15, wherein the second electrical signal has a frequency of about 200 Hz to about 10 kHz.

18. 14. The system of claim 1, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz and the second electrical signal has a frequency of about 200 Hz to about 10 kHz.

19. 19. The system of claim 1, wherein the first electrical signal and / or the second electrical signal each independently include a signal pattern, each signal pattern including pulses having a pulse width of about 0.1 microseconds to about 10,000 microseconds.

20. The system of any one of claims 1 to 19, wherein the pulses of the first and / or second electrical signals are monophasic pulses, or biphasic pulses, or a combination thereof.

21. 21. The system of any one of claims 1 to 20, wherein the first and / or second electrical signals each independently have an on-time of from about 30 seconds to about 30 minutes.

22. 22. The system of any one of claims 1 to 21, wherein the first and / or second electrical signals each independently have a current amplitude in the range of about 0.01 mAmps to about 20 mAmps.

23. 23. The system of any one of claims 1 to 22, wherein the first and / or second electrical signals each independently comprise a sudden onset of a pulse, or an increase in current / voltage amplitude, or an increase in frequency, or an increase in pulse width, or a combination thereof, at or near the start of application of the first and / or second electrical signal.

24. 24. The system of any one of claims 1 to 23, wherein the first and / or second electrical signal therapies are configured to be applied intermittently multiple times per day and over multiple days, and the first and / or second electrical signals each have a frequency selected to upregulate activity on the first nerve or organ and have an on-time and an off-time, the off-time selected to allow at least partial recovery of the activity of the first nerve or organ.

25. The system of any one of claims 1 to 24, wherein the programmable storage and communication module is configured to store and communicate two or more therapy programs, each therapy program being different from the others and configured to be selected for communication.

26. 26. The system of any one of claims 1 to 25, further comprising a transmitter operably connected to the glucose sensor, the transmitter configured to communicate data generated by the glucose sensor to an external communication device.

27. 27. The system of any one of claims 1 to 26, wherein the communication system is selected from the group consisting of an antenna, blue tooth technology, radio frequency, WIFI, light, sound, and combinations thereof, and the communication system is configured to communicate parameters of the at least one therapy program to an external communication device.

28. 1. A method of treating type 2 diabetes in a subject, comprising:

2. Using the system of claim 1, applying a first electrical signal to a first nerve or organ of the subject, the first electrical signal initiating nerve stimulation or a nerve block; Optionally, the method includes applying a second electrical signal to a second nerve or organ of the subject using the system of claim 1, the second electrical signal initiating nerve stimulation or a nerve block.

29. 30. The method of claim 28, wherein the first and second electrical signals are applied simultaneously, synchronously, intermittently, during substantially the same time, during substantially different times, or in a coordinated manner.

30. 30. The method of claim 28 or 29, wherein the first and / or second electrical signal is configured to increase plasma glucose in the subject by at least about 5 mg / dL in about 10 minutes.

31. 31. The method of any one of claims 28-30, wherein the first and / or second electrical signal therapies are configured to change the plasma glucose level by at least about 10 mg / dL in about 20 minutes.

32. 32. The system of any one of claims 28-31, wherein the first and / or second electrical signal therapies are configured to change the plasma glucose level by at least about 20 mg / dL in about 30 minutes.

33. 33. The method of any one of claims 28 to 32, wherein the first and / or second electrical signals are each applied continuously for an on-time followed by an off-time during which no signal is applied to the nerve or organ.

34. 34. The method of any one of claims 28-33, wherein the on-time is applied multiple times per day when plasma glucose levels are about 50 mg / dL, about 60 mg / dL, about 70 mg / dL, or about 80 mg / dL.

35. 35. The method of any one of claims 28-34, wherein the off-time is applied multiple times per day when plasma glucose levels are greater than about 80 mg / dL to about 90 mg / dL, or greater than about 100 mg / dL, or greater than about 110 mg / dL.

36. 36. The method of any one of claims 28 to 35, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz.

37. 36. The method of any one of claims 28 to 35, wherein the first electrical signal has a frequency of about 200 Hz to about 10 kHz.

38. 38. The method of any one of claims 28 to 37, wherein the second electrical signal has a frequency of about 0.01 Hz to about 200 Hz.

39. 38. The method of any one of claims 28 to 37, wherein the second electrical signal has a frequency of about 200 Hz to about 10 kHz.

40. 36. The method of any one of claims 28 to 35, wherein the first electrical signal has a frequency of about 0.01 Hz to about 200 Hz and the second electrical signal has a frequency of about 200 Hz to about 10 kHz.

41. 41. The method of any one of claims 28-40, wherein the first nerve or organ and the second nerve or organ are independently selected from the group consisting of the vagus nerve, anterior vagus nerve, posterior vagus nerve, posterior nerve hiatus, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof.

42. 42. The method of any one of claims 28 to 41, wherein the first nerve or organ and the second nerve or organ are different.

43. 43. The method of any one of claims 28 to 42, wherein the first electrical signal is applied to a hepatic branch of the vagus nerve or abdominal vagus nerve centered at the bifurcation of the hepatic nerve.

44. 43. The method of any one of claims 28 to 42, wherein the first electrical signal is applied to the vagus nerve, centered at the bifurcation of the celiac nerve, or the celiac branch of the abdominal vagus nerve.

45. 43. The method of any one of claims 28 to 42, wherein the first electrical signal is applied to the liver, the pancreas, or both.

46. 46. ​​The method of any one of claims 28 to 45, wherein the second electrical signal is applied to a splanchnic nerve, or the celiac branch of the vagus nerve, or to the pancreas.

47. The method of any one of claims 28 to 45, wherein the second electrical signal does not participate in the method.

48. 48. The method of any one of claims 28 to 47, further comprising administering an agent that improves glucose control.

49. 49. The method of claim 48, wherein the agent reduces the amount of insulin and / or reduces the sensitivity of cells to insulin.

50. 1. A method of making a system for treating type 2 diabetes in a subject, comprising: connecting a first electrode to a pulse generator and positioning the first electrode on a first nerve or organ; Optionally, connecting a second electrode to the pulse generator and placing the second electrode on a second nerve or organ; configuring a programmable therapy delivery module of the pulse generator to deliver at least one therapy program including a first electrical signal therapy and optionally a second electrical signal therapy, the first electrical signal therapy being configured to be applied to the first nerve or organ via the first electrode and the second electrical signal therapy being configured to be applied to the second nerve or organ via the second electrode, the first and / or second electrical signals initiating nerve stimulation or nerve block, respectively; and configuring a programmable storage and communications module of an external component to store the at least one therapy program and to communicate the at least one therapy program to the pulse generator.

51. 51. The method of claim 50, wherein the first and / or second electrical signals each have a frequency selected to initiate activity on the first and / or second target nerves or organs, respectively, and the activity is upregulation or downregulation of neural activity.

52. 52. The method of claim 50 or 51, further comprising connecting a glucose sensor to the pulse generator and using the glucose sensor to monitor or detect a plasma glucose level in the subject.

53. 53. The method of any one of claims 50 to 52, further comprising configuring a communication system of the external component to communicate parameters of the at least one therapy program to an external communication device.

54. 54. The method of any one of claims 50 to 53, further comprising connecting a transmitter to the glucose sensor to communicate data generated by the glucose sensor to an external communication device.

55. 55. The method of any one of claims 50 to 54, wherein the first and / or second electrodes are positioned on the nerve or organ via a laparoscopic approach.

56. 1. A system for treating diabetes in a subject, comprising: at least one electrode positioned on a nerve or organ of the subject and adapted to deliver an electrical signal to the nerve or organ of the subject; a pulse generator operably connected to the at least one electrode, the pulse generator comprising a power module and a programmable therapy delivery module, the programmable therapy delivery module configured to deliver at least one therapy program, the at least one therapy program including at least one electrical signal therapy applied to the nerve or organ via the at least one electrode; an external component including a communication system and a programmable storage and communication module, the programmable storage and communication module configured to store the at least one therapy program and to communicate the at least one therapy program to the pulse generator; a glucose sensor operatively and communicatively connected to the pulse generator and the external component, the glucose sensor configured to continuously monitor plasma glucose of the subject and to detect an increase or decrease in plasma glucose from a predetermined threshold level; the pulse generator is triggered to deliver the at least one electrical signal therapy when the subject's plasma glucose is below a first predetermined threshold, and the pulse generator stops delivering the at least one electrical signal therapy when the subject's plasma glucose is above a second predetermined threshold; The system, wherein the at least one electrical signal therapy is configured to initiate neural stimulation to the nerve or organ of the subject.

57. 57. The system of claim 56, wherein the nerve or organ is selected from the group consisting of the vagus nerve, anterior vagus nerve, posterior vagus nerve, hiatus of the posterior nerve, hepatic branch of the vagus nerve, celiac branch of the vagus nerve, splanchnic nerve, renal nerve, renal artery, sympathetic nerve, baroreceptor, glossopharyngeal nerve, duodenum, jejunum, ileum, small intestine, colon, stomach, esophagus, liver, spleen, pancreas, and combinations thereof.

58. 58. The system of claim 56 or 57, wherein the nerve is the subject's posterior vagus nerve (PVN) or the celiac vagus branch of the PVN.

59. 59. The system of any one of claims 56 to 58, wherein the electrical signal has an on-time and an off-time, the off-time selected to allow at least partial recovery of the activity of the nerve or organ.

60. 60. The system of claim 59, wherein the on-time is configured to begin upon the detection of a plasma glucose level in the subject of about 50 mg / dL or less, about 60 mg / dL or less, about 70 mg / dL or less, or about 80 mg / dL or less.

61. 61. The system of claim 59 or 60, wherein the on-time is from about 30 seconds to about 30 minutes.

62. 62. The system of any one of claims 56-61, wherein the at least one electrical signal therapy comprises an electrical signal pattern having a frequency of about 1 Hz to about 200 Hz, or about 1 Hz to about 50 Hz, or about 1 Hz to about 20 Hz, or about 1 Hz to about 10 Hz, or about 1 Hz to about 5 Hz, or about 1 Hz to about 2 Hz.

63. 63. The system of any one of claims 56 to 62, wherein the electrical signal pattern has pulse widths from about 0.1 microseconds to about 10 microseconds in steps of about 0.1 microseconds.

64. 64. The system of any one of claims 56 to 63, wherein the electrical signal pattern has a pulse amplitude of about 0.1 mA to about 12 mA in steps of about 0.1 mA.

65. 65. The system of any one of claims 56 to 64, wherein the pulses of the at least one electrical signal are monophasic pulses, or biphasic pulses, or a combination thereof.

66. 66. The system of any one of claims 56 to 65, wherein the at least one electrical signal further comprises a sudden onset of a pulse, or an increase in current / voltage amplitude, or an increase in frequency, or an increase in pulse width, or a combination thereof, at or near the start of application of the electrical signal.

67. 67. The system of any one of claims 56-66, wherein at least one electrical signal therapy is configured to be applied multiple times per day and intermittently over multiple days.

68. 68. The system of any one of claims 56-67, wherein the at least one electrical signal therapy is configured to increase the plasma glucose in the subject by at least about 5 mg / dL in about 10 minutes, or at least about 10 mg / dL in about 20 minutes, at least about 20 mg / dL in about 30 minutes, or at least about 30 mg / dL in about 45 minutes, or at least about 40 mg / dL in about 60 minutes.

69. 69. The system of any one of claims 56-68, wherein the at least one electrical signal therapy is configured to cause an increase in insulin secretion in the subject.

70. 70. The system of any one of claims 56-69, wherein application of the at least one electrical signal therapy is configured to cause a decrease in insulin secretion in the subject.

71. 71. The system of any one of claims 56 to 70, further comprising a transmitter operably connected to the glucose sensor, the transmitter configured to communicate data generated by the glucose sensor to an external communication device.

72. 72. The system of any one of claims 56-71, wherein the communication system is selected from the group consisting of an antenna, blue tooth technology, radio frequency, WIFI, light, sound, and combinations thereof, and wherein the communication system is configured to communicate parameters of the at least one therapy program to an external communication device.

73. 1. A method of treating type 2 diabetes in a subject in need thereof, comprising:

73. A method comprising applying the at least one electrical signal therapy to a subject's posterior vagus nerve (PVN) or the celiac vagus nerve branch of the PVN of the subject using a system according to any one of claims 56 to 72.

74. 74. The method of claim 73, wherein the electrical signal pattern applied to the has a frequency of about 1 Hz to about 20 Hz, a pulse width of about 0.1 microseconds to about 10 microseconds in steps of about 0.1 microseconds, and a pulse amplitude of about 0.1 mA to about 12 mA in steps of about 0.1 mA.

75. 75. The method of claim 73 or 74, wherein application of the at least one electrical signal therapy increases the plasma glucose in the subject by at least about 5 mg / dL, at least about 10 mg / dL, at least about 20 mg / dL, at least about 30 mg / dL, at least about 40 mg / dL, at least about 50 mg / dL, at least about 60 mg / dL, at least about 70 mg / dL, at least about 80 mg / dL, at least about 90 mg / dL, or at least about 100 mg / dL in about 60 minutes.

76. 76. The method of any one of claims 73-75, wherein application of the at least one electrical signal therapy causes an increase in insulin secretion in the subject.

77. 77. The method of any one of claims 73 to 76, wherein the application of the at least one electrical signal therapy causes a decrease in insulin secretion in the subject.

78. 78. The method of any one of claims 73 to 77, further comprising placing the at least one electrode on the nerve or organ via a laparoscopic approach.

Citation Information

Patent Citations

  • Methods and systems for glucose regulation

    CN102056645A

  • Treatment of conditions associated with impaired glucose control

    CN109562264A

  • Simultaneous multi-site vagus nerve neuromodulation for improved glycemic control system and methods

    CN112423838A

  • Methods and systems for glucose regulation

    JP2011516177A

  • Treatment of conditions associated with impaired glucose control

    JP2019516497A